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ABSTRACT
Characterization of Neuronal Nicotinic Acetylcholine Receptors
and Their Positive Allosteric Modulators
Doris Clark Jackson
Department of Physiology and Developmental Biology, BYU
Doctor of Philosophy
Neuroscience
Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels that are
necessary in memory and cognition. They are pentameric and consist of α and β subunits. They
are most commonly heteromeric but, can sometimes be homomeric. nAChRs are activated by
many ligands including nicotine (exogenous) and acetylcholine (endogenous).
nAChRs are located on hippocampal interneurons. The interneurons, although sparse, control
the synchronous firing of the pyramidal cells. However, the hippocampal interneuron structure
and function is quite diverse and not fully characterized. Therefore, we sought to quantify
nAChR subunit mRNA levels using real-time PCR of CA1 hippocampal interneurons.
Surprisingly we found that the α3 and β2 mRNA subunits were the highest expressed and highest
co-expressed subunits. Additionally, the α4 mRNA subunit was the lowest expressed of the
subunits detected. The α4 subunit is one of the most pharmacologically targeted nAChR
subunits and is found throughout the rest of the brain at much higher levels than the α3 mRNA
subunit. Upon PCR analysis two subpopulations of the α3 and β2 subunits emerged: those that
contained 3X more α3 than β2 and those that contained 3X more β2 than α3. Therefore, we
hypothesized that two likely α3β2 nAChR stoichiometries are present in hippocampal
interneurons. We differentiated their kinetic properties using electrophysiology.
Additionally, like the α4 subunit, the α7 subunit is highly targeted in cognitive therapeutics.
Since, the α7 subunit is the most characterized nAChR subunit, there are current efforts to
develop allosteric modulators of the α7 subunit. The α7 subunit is found at moderate levels
within hippocampal interneurons and remains a valid target. Current treatment options for
Alzheimer’s disease, and other dementias are limited and only mildly effective. Therefore, we
sought to characterize the effect of 3-furan-2-yl-N-p-tolyl-acrylamide (PAM-2) on α7.
Furthermore, there are no current methods to distinguish the α7 from the α7β2 nAChRs during
whole cell electrophysiological recordings. Therefore, we also characterized the PAM-2 effect
on α7β2 nAChRs. Our results highlight at least 2 ways PAM-2 can be used to differentiate α7
from the α7β2 during whole-cell recordings.
Keywords: nicotinic acetylcholine receptors (nAChRs), hippocampus, interneurons,
electrophysiology, allosteric modulators, real-time PCR
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INTRODUCTION
Nicotinic acetylcholine receptors (nAChR) are ligand-gated ion channels that are found
in the central nervous system (CNS), peripheral nervous system (PNS), and in skeletal muscle at
the neuromuscular junction. nAChRs are integral membrane proteins that create cation
permeable pores in the extracellular membrane of cells when the neurotransmitter acetylcholine
(ACh) binds. In the PNS and skeletal muscle, they are located post-synaptically, in the classic
role of a neurotransmitter receptor that awaits signals from the presynaptic cell. In the CNS
however, they can be located pre-terminally, pre-synaptically, and post-synaptically. When
located post-synaptically, they function as a normal ligand-gated ion channel, changing the
membrane potential of excitable cells like neurons and skeletal muscle when activated.
However, when located pre-synaptically, they function in a unique role as modulators for the
release of other neurotransmitters like glutamate, GABA, serotonin, dopamine, and
acetylcholine.
Each nAChR contains 5 subunits making it a pentameric receptor. Different subunit
combinations create different functional receptor subtypes. The skeletal muscle nAChR is
formed from combinations of the α1, β1, γ, δ and ε subunits. There are 11 known human genes
for neuronal nAChR subunits (α2-7, α9-10, and β2-4) (Rubboli et al., 1994, Sargent, 1993). The
most common combinations require two α subunits and three β subunits, or three α subunits and
two β subunits. Only the α7 and α9 subunits can form homomers. Given the tremendous
possible diversity of neuronal nAChR subtypes, many of the potential pentameric combinations
are not fully characterized.
Receptors made from different subunit combinations create receptor subtypes that have
different physical properties. These include pharmacological properties like agonist and

1

antagonist affinity, and kinetic properties like activation, inactivation and desensitization rates.
Additionally, nAChR subtypes can have different ion permeabilities. All nAChR subtypes are
permeable to Na+ and K+, but some subtypes like the α7 homomer are also highly permeable to
Ca2+, which allows for activation of a variety of intracellular signaling cascades. The
hippocampal interneurons we analyzed are GABAergic neurons and release GABA unto the
pyramidal cells resulting in inhibition. Since these interneurons synapse with hundreds of
pyramidal cells, the interneurons play a vital role in the synchronous firing of the hippocampus.
The hippocampus has an organized firing pattern. In the major hippocampal pathway
called the “trisynaptic circuit,” axons enter the hippocampus from the entorhinal cortex and
terminate on glutamatergic neurons in the dentate gyrus (DG). The signals then travel from the
dentate gyrus to the CA3 region of the hippocampus via the “mossy fibers” (glutamatergic). The
third synapse (also glutamatergic) goes from the CA3 region to the CA1 region of the
hippocampus (Figure 1) in what are called the “Schaffer collaterals” (Grybko, Sharma, &
Vijayaraghavan, 2010). An additional input comes at this stage from the contralateral
hippocampus, known as the commissural fibers. This maintains communication between both
hemispheres of the hippocampus. Finally, the CA1 region of the hippocampus sends an output
signal to the subiculum.
As stated, the pyramidal cells of the hippocampus must fire their output signal
synchronously. The nAChRs located in interneurons play a crucial role in the synchronous firing
of the hippocampus required for normal cognition. Memory is correlated with theta and gamma
frequencies of the pyramidal cells, whereas, attention is correlated with alpha and gamma
frequencies (Ward, 2003). It has been shown that desynchronization of this firing can result in a
loss of cognition (Hanslmayr, 2012, Mitchell, 2009). Additionally, cognitive diseases like
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Alzheimer’s disease are characterized by neurodegeneration of the hippocampus. The
neurodegeneration disrupts the interneuron-pyramidal cell relationship.
We analyzed the nAChR subunit mRNAs in the CA1 hippocampal interneurons to
elucidate the most likely nAChR subtypes expressed on hippocampal interneurons (circled in
Figure 1). Our results could lead to improved nAChR targeted therapies in the treatment of
cognitive disorders by identifying the most likely targets on hippocampal interneurons.
Specifically our work focused on interneurons of the stratum oriens and stratum radiatum
surrounding the CA1 pyramidal neurons (Figure 2) (Graham et al., 2003, Son & Winzer-Serhan,
2006). Using single-cell, real time-PCR (qPCR), we identified the expression of α2, α3, α4, α5,
α7, β2, β3, and β4 subunit mRNA in rat hippocampal interneurons. The α6 mRNA subunit was
not detected during initial analysis, and therefore, was removed from continued experiments.
Statistical analysis of our single-cell qPCR mRNA expression data suggests that the α3 and β2
subunits colocalize more often than any other subunit pair (Sargent, 1993; Wada et al., 1989).
However, the characterization of receptors containing the α3β2 subunits is still in its infancy.
The current thinking suggests that the most likely stoichiometry is α3(2)β2(3), based mainly on
evidence from the muscle nAChR and the α4β2 neuronal nAChR – which is thought to contain
two α subunits in its pentameric makeup. However, recent experiments involving other α:β
combinations that have been better characterized, like the α4β2 and α2β2 subunits, indicate that
the most likely functional receptors would be α3(2)β2(3) or α3(3)β2(2) (Lukas 1988, Moroni et al.,
2008, Wu et al., 2006, Zwart et al., 2008). Other stoichiometries are possible, but less likely. In
addition, the α3β2 nAChR receptors would likely incorporate additional nAChR subunits such as
the α5 subunit – further complicating the native subtypes of the receptor (ChavezNoriega et al.,
1997, Wada et al., 1989).
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The results of our work quantifying the nAChR subunits mRNAs revealed a highly
heterogeneous population of nAChR subunit mRNAs. Furthermore, the α3 subunit is very
limited in its expression in other brain regions, possibly making the α3β2 nAChR a valuable
therapeutic target for cognitive diseases. Targeting the α3β2 may result in fewer undesired
effects while still achieving cognitive improvements. Therefore, we sought to characterize the
α3β2 nAChR as a potentially important receptor in hippocampal circuitry.
We characterized this novel receptor—the α3β2—in a simplified cell expression system.
We used Xenopus laevis oocytes because they are extremely large cells, and when injected with
foreign mRNA can produce many channels (i.e., large currents). Additionally, Xenopus laevis
oocytes do not express native acetylcholine receptors. Also, since these oocytes allow for easier
access to the cell surface we can better analyze the ion channel kinetics than neurons in brain
slices. The time required for a solution to travel through brain tissue to the channel of interest is
not as precise making the interpretation of kinetic data more difficult (Charpantier et al., 2005,
ChavezNoriega et al., 1997, Dash, Bhakta, Chang, & Lukas, 2012, Ruud & Henk P. M.
Vijverberg Research Institute of Toxicology, 1998).
Previous work has shown that agonists of nAChRs, like nicotine, can improve cognition
in low-doses (Houezec, 1993, Levin, 2002, Sacco, 2004). Conversely, nAChR antagonists
impair cognition (Levin, 2002). Additionally, both the α7 and β2 knockout mice show
impairment in working memory (Fernandes, 2006, Hoyle, 2006, Levin, 2009). Furthermore, a
genome-wide association study, also known as GWAS, shows that the β4 subunit is related to
attention function in attention deficit hyperactive disorder. Chapter 3 will highlight a new class
of drugs targeting nAChR called positive allosteric modulators. They are not agonists but, do
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cause an increase in receptor conductance upon activation. This type of modulation may
improve cognition like nAChR agonists.
One of the potential therapeutic implications for understanding the role of neuronal
nAChRs in hippocampal interneurons is Alzheimer’s Disease (AD). The neurons that
degenerate first in AD are cholinergic neurons that have synapses with the GABAergic
interneurons of the hippocampus (Liu et al., 2009). Since the GABAergic interneurons receive
signaling from the cholinergic neurons, the GABAergic neurons contain nAChRs and are the
population of neurons analyzed in Chapter 1. The International Alzheimer’s Association reports
that currently 5 million Americans are living with AD and the number continues to rise. More
people die annually of AD than breast cancer and prostate cancer combined, making it the 6th
leading cause of death in the United States. The disease impacts the individual as well as the
caregivers, the family, and their communities. With years of research dedicated to heart disease
and cancer, the disease prevalence of both heart disease and cancer have declined and treatment
has improved. The hope is that with continued research in AD we can turn the tide of disease
progression and improve treatment options as well.
One of the first signs of AD is memory loss. Unfortunately, when memory loss is first
observed, AD has been present for years and has progressed significantly (Mattson, 2004). At
this stage of disease, there is little that can be done to halt disease progression or improve quality
of life (Corbett, Smith, & Ballard, 2012, Mattson, 2004). Of the treatment options currently
available, there is little, if any improvement, for up to six months before improvement becomes
negligible.
The most promising method of nAChR targeted therapy in the treatment of cognitive
disorders is allosteric modulation. Allosteric modulators bind to a distinct site from the ACh
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binding site, and cannot activate the receptor independently. Allosteric modulators require both
the binding of the modulator and a ligand to elicit an effect. Allosteric modulation can be
positive, negative, or silent. With the binding of a ligand, positive allosteric modulators increase
the potentiation, or current, of the electrical signal. Negative allosteric modulators inhibit the
electrical signal, but only in the presence of a ligand. Silent allosteric modulators do not
potentiate or inhibit the current, but will remove the effect of a positive or negative allosteric
modulator.
To further characterize nAChR subtypes, we used positive allosteric modulators to
differentiate α7 and α7β2. The most widely characterized nAChR subtype is the homomeric α7.
Recent evidence highlights the presence of α7β2 throughout the brain (Moretti, 2014). However,
during whole cell, and even single channel recordings, it is extremely difficult to differentiate the
subtypes from one another. There is no reliable method in whole cell patch clamp experiments
to differentiate using current kinetic analysis or pharmacology. In Chapter 3, we characterize the
different effect 3-furan-2-yl-N-p-tolyl-acrylamide (PAM-2) has on α7 and α7β2. Although there
are many similar PAM-2 effects on each subtype, we do demonstrate at least 2 ways that PAM-2
can be used to differentiate the α7 from the α7β2.
In conclusion, the following experiments predict possible nAChR subtypes that may be
found in hippocampal interneurons and differentiate between subtypes of the α3β2 nAChR.
Additionally, PAM-2 may be a promising drug in the treatment of cognitive disorders as it
greatly potentiates the conductance of α7* nAChR. Furthermore, we introduce at least 2 ways
PAM-2 can be used to differentiate α7 and α7β2 nAChRs.
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Figure I.1

Figure I.1: The Cellular Components of Each Region of the Hippocampus. Specifically,
the pyramidal neurons of the CA3 and CA1 regions and the interneurons of the CA1.
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Figure I.2

Figure I.2: The Cellular Layers Within the CA1 Region of the Hippocampus.
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Abstract
Pyramidal cells are the most populous neurons in the hippocampus, yet they are controlled
by a sparse population of inhibitory interneurons. However, the hippocampal interneurons are
not well understood and are quite diverse on many fronts. Using qPCR of CA1 hippocampal
interneurons, we quantified mRNA subunits expression and detailed possible combinations. We
also highlighted differences found between the stratum oriens and the stratum radiatum.
We show that almost all interneurons in the CA1 of the rat hippocampus contain detectable
levels of nicotinic acetylcholine receptor (nAChR) mRNA. Our research highlights the
complexity of the CA1 nAChR population. Interestingly, the α3 nAChR subunit is one of the
highest expressed subunit mRNAs while the α4 is one of the least likely subunits to be detected
in the CA1 interneurons. Not as surprisingly, the β2 nAChR subunit is the other highest
expressed mRNA. In addition, the subunit co-expression Pearson correlation values highlight
key differences between the stratum oriens and the stratum radiatum. Our estimation is that
there are approximately 119 different mRNA combinations that are likely in rat CA1
interneurons.
These results provide a new and valid avenue in cognitive therapies by targeting α3
containing nAChRs. Currently, the nAChR targeted cognitive therapies focus on the α4β2
nAChR and the α7 nAChR.

This new insight may improve therapies for Alzheimer’s Disease,

Autism Spectrum Disorder, Dementia, and Attention-Deficit Hyperactivity Disorder.
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Introduction
Understanding the scope of expression of nicotinic acetylcholine receptors (nAChRs)
within the interneurons of the hippocampus would lend great insight for cognitive therapies used
in Alzheimer’s Disease (AD), Attention-Deficit Hyperactivity Disorder (ADHD), Autism
Spectrum Disorder (ASD), and Post-Traumatic Stress Disorder (PTSD). The GABAergic
interneurons are controlled by nAChRs found on their dendrites, soma, and on the axon terminal
(Jones, 1997). These GABAergic neurons control the synchronous firing of the highly populated
pyramidal neurons (Cobb, 2005). Therefore, modulation of the nAChRs contributes to the
regulation of glutamatergic pyramidal neurons (Ji, 2000).
When considering our electrophysiological results, we suspect that the nAChR assembly
is made of various combinations of eight subunits: α2-α5, α7, and β2-β4. The nAChRs in
hippocampal interneurons are in a key position to modulate cognitive functions because
interneurons play a major role in coordinating hippocampal activity, reviewed in Freund (1996).
Accordingly, nAChRs have been implicated in diseases affecting cognition, of which
Alzheimer’s disease is the most principal (Gray, 1996).
Compositional variations of nAChR subunits within the hippocampus have been shown
to mediate nicotinic receptor kinetics (Sudweeks, 2000) and enable plasticity in interneuron
function (Alkondon, 2001). Of the neuronal nAChR subunits, α7 has been studied most
extensively. Use of subunit-specific antagonists to α7 homomeric receptors (either αbungarotoxin or methyllycaconitine) has provided an important tool in isolating contributions of
this subunit in receptor kinetics, physiology, and disease. High-affinity binding, for example,
has been shown for α7 to β-amyloid, a peptide implicated in Alzheimer’s disease (Wang, 2000),
which binding results in the blockage of current flow through the nAChR (Pettit, 2001). There
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are many functional roles (and resultant diseases or disorders) attributed to the α7 nAChR
(within and outside of the hippocampus) including depression, cognition, gastric cancer, and
memory (Zhang, 2016, Chen, 2015).
The paucity of other highly subunit-specific antagonists of the nAChR has impeded
progress in characterizing the roles of other subunit combinations to the extent of α7. Until more
subunit-specific agents are discovered, other means for characterizing the individual nAChR
subunits must be utilized. On-going studies to characterize the extent of nAChR subunit coexpression within individual neurons may identify trends shared by functionally distinct
networks or subpopulations of neurons (Jones, 1999). In addition, the identification of coexpression trends between nAChR subunits and other neurochemical markers may facilitate
more comprehensive characterization of the nAChR and of neuronal subpopulations. Therefore,
we sought to differentiate and classify hippocampal interneuron expression of neuronal nAChR
subunit mRNA through single-cell qPCR.
Methods
Slice Preparation
All CA1 hippocampal slice and interneuron aspiration experiments were prepared and
carried out as described previously (Sudweeks, 2000). In brief, to obtain the interneurons,
coronal brain slices (either 300 or 350 μm thick) were made from 8 to 23 day old Wistar rats
using a Vibratome 1000-Plus. The slices were cut in ice-cold oxygenated (95% O2, 5% CO2)
artificial cerebrospinal fluid and placed in room-temperature oxygenated ACSF for at least 30
minutes prior to placing in microscope recording chamber. IUCAC approval was obtained for all
animal experiments.
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Cytoplasm Aspiration
An upright microscope with infrared light was used to individual hippocampal interneurons
from the Amun’s horn (CA1) stratum oriens and stratum radiatum were visually identified as
neurons outside the pyramidal cell layer. Interneurons were then aspirated into a standard
whole-cell patch-clamp pipette containing 5 μL Intracellular Fluid as described previously
(Sudweeks, 2000).
Electrophysiology
A whole-cell recording configuration of the interneuron was obtained in voltage-clamp
mode prior to cytoplasm aspiration. Interneuron membrane potentials were held at -70mV.
Where recordings were performed, responses were induced by the gravity flow application of 1
mM ACh for 1 second, using an Axon 200. Whole-cell recordings were filtered at 1 kHz, and
sampled at 100 Hz, using the pCLAMP Clampex software (version 7.01.31, Axon Instruments).
Acetylcholine (ACh) was applied using an electronically triggered valve (General Valve Co.,
Fairfield, NJ, USA) connected to a synthetic quartz tube (inner diameter of 320 µm, Polymicro
Technologies Inc., Phoenix, AZ, USA) placed approximately 90—120 µm from the cell body.
The flow rate for the ACh application from the gravity flow perfusion system was 250 µl min. A
washout period of at least 3 min was included between subsequent recordings.
Primers and Probes
The primers and probes were designed using either Vector NTI version 7.0 (Invitrogen) or
Primer Express version 2.0 (ABI Prism) software.
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RT Reaction
A cDNA library representing each CA1 hippocampal interneuron was made by running a
reverse transcription reaction using BIORAD iScript cDNA Synthesis Kit with a final volume of
10 μl.
Multiplex Reaction and Real-time Quantitative PCR
A multiplex PCR reaction was run (15 cycles) for each aspirated interneuron using all
neuronal nAChR primers and the primer for 18s rRNA (see Table 1 and Table 2) with a final
volume of 75 μl. The α6 subunit was not examined because initial experiments showed no
detection of this subunit in any hippocampal interneurons examined. The multiplex reaction was
run using Platinum® Taq DNA Polymerase and PCR nucleotides (10mM). A second round of
PCR was run (60 cycles) for each specific target (18s, α2−α5, α7, β2, β3, β4) using an ABI
7000 Sequence Detection System utilizing BIORAD iTaq Supermix with ROX. Cycle threshold
values for each target were compared to the reference gene 18s for analysis (more in Real-Time
Analysis).
Standard curves (efficiency tests) for each cDNA target were developed by running 60cycle real-time quantitative PCR assays on positive controls (rat whole-brain homogenate) for
six known concentrations (100, 33.3, 10, 3.33, 1, 0.333 ng cDNA/μL). Two types of negative
controls were run as well. First, we aspirated extracellular fluid and tested for the presence of
nAChR mRNA. Any subunit that had a cycle threshold greater than the mRNA detected in the
extracellular fluid was omitted from that interneuron’s profile. The second negative control was
to simply run the quantitative PCR assay with no cellular components. This was used to detect
any mRNA contaminants.
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To correct the standard curves for efficiency so all mRNAs were equally efficient,
upstream (primer +) and downstream (primer –) primer concentrations were adjusted to optimize
amplification. The efficiency of the amplification reaction is calculated using the slope of the
log(concentration) vs. CT plot. The formula for PCR efficiency = 10

( −1 / slope )

− 1 (Bustin,

2004). Reaction efficiencies were run in triplicate and the amplification efficiencies were
compared using an ANOVA to determine if there were significant differences between any of the
primer/probe sets (18s, α2−α5, α7, β2, β3, β4 ).
To calculate primer efficiencies, triplicate reactions of each cDNA target were averaged
and a linear regression equation was calculated (SLOPE function, Microsoft Excel) of the CT
values corresponding to the six known concentrations (100, 33.3, 10, 3.33, 1, 0.333 ng
cDNA/μL) in the standard curve primer efficiency tests. The PCR efficiency was then
determined by incorporating the slope of the linear equation using the formula described above
(see Multiplex Reaction and Real-time Quantitative PCR) (Burgon 2005).
Data and Statistical Analysis
Following the real-time quantitative PCR on hippocampal interneurons, raw fluorescence
(ΔRn) values across 60 cycles were curve-fit using a Boltzmann Sigmoidal function with an
output of either 2000 or 4000 data points in the new curve using GraphPad v. 4.0 software. The
second derivative graph for the curve-fit data was then determined, also using Graphpad. The
cycle threshold (CT) value used was the cycle number of the maximum second derivative value
of the fluorescence.
For comparison of expression levels between cDNA targets, fold expression values from
the triplicate CT averages were calculated as compared to the lowest level of cDNA detection
using the 2-ΔΔCt method described by Livak (2001). Significance between relative levels of
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mRNA expression was calculated by comparing mean fold expression values using a MannWhitney test (calculated using InStat ver. 3.05). Blinding was not used because it is not an
appropriate approach to mRNA expression analysis or qPCR.
For the qPCR analysis, the proportion of neurons expressing a particular mRNA is equal
to the number of observed positive neurons divided by the total number of neurons analyzed for
that mRNA transcript. The standard error of the proportion (S.E.P.) was calculated for each
mRNA transcript examined using the following formula (Moore, 1995):
Equation 1:

where p = the proportion of neurons in the population with detectable expression, and n = the
number of neurons in that population.
To test for significant expression of each mRNA when compared to the background
qPCR calculated false positive proportion, and to compare the mRNA expression of the two
populations with functional nAChR responses, we used a z-test for comparing two sample
proportions. The formula is (Moore and McCabe, 1995):
Equation 2:

pˆ1-pˆ2
z=
ˆ ˆ
p(1-p)

(

1
1
+
n1
n2

)

where pˆx is the proportion of cells with detected expression in each population, nx is the number
ˆ
ˆ
ˆ
of neurones examined in that population, and p (no subscript) is the pooled estimate of p1 and p2.
ˆ
The calculation for p is (Moore and McCabe, 1995):
Equation 3:

pˆ =

Total count of successes in both samples
Total count of observations in both samples combined
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Each z-value was compared to a normal curve using the Excel NORMSDIST(absolute
value of z) function, which gives the probability (p) that the two proportions are equal. The
proportions were considered significantly different when p<0.01.
Materials
Artificial cerebrospinal fluid: 124 NaCl, 2 KCl, 1 NaH2PO4, 26 NaHCO3, 11 Glucose, 2 CaCl2, 1
MgSO4 (in mM): Sigma-Aldrich, 3050 Spruce Street, St. Louis, MO 63103 USA.
All primers, all probes, Vector NTI version 7.0, Platinum® Taq DNA Polymerase, PCR
nucleotides: Invitrogen/Thermo Fisher Scientific, 168 Third Avenue, Waltham, MA USA
02451 USA.
Vibratome 1000-Plus: Pelco, Ted Pella, Inc., P.O. Box 492477, Redding, CA 96049-2477 USA.
Nikon E600-FN Microscope: A.G. Heinz, 20291 Valencia Circle, Lake Forest, CA 92630-8155
USA.
Borosilicate capillaries: Harvard Apparatus, 84 October Hill Road, Holliston, Massachusetts
01746 USA.
Intracellular Fluid: 10 MgCl2, 0.1 CaCl2, 1 EGTA, 10 HEPES, 135 K-Gluconate, and 2 Na-ATP
(in mM): Sigma-Aldrich, 3050 Spruce Street, St. Louis, MO 63103 USA.
Multiclamp 700A: Axon Instruments/Molecular Devices, 1311 Orleans Drive, Sunnyvale, CA
94089 USA.
ABI 7000 Sequence Detection System and Primer Express version 2.0, ABI Prism: Applied
Biosystems, 850 Lincoln Centre Drive, Foster City, CA 94404 USA.
iScript cDNA Synthesis Kit and iTaq Supermix with ROX: BIORAD, 2000 Alfred Nobel Drive,
Hercules, California 94547 USA.
GraphPad v. 4.0 and GraphPad Instat v. 3.05: GraphPad Software, Inc., 7825 Fay Avenue, Suite
230, La Jolla, CA 92037 USA.
Microsoft Excel: Microsoft Building 92, 15010 NE 36th St, WA 98052-6399 USA.
Results
Our results highlight the heterogeneity of nAChR mRNAs in the hippocampal
interneurons as demonstrated by the variety of kinetic responses during whole-cell
electrophysiology and ACh applications (Figure 1). We sought to dissect the population of
nAChR subtypes by through single cell real-time-PCR (qPCR) of the stratum oriens and stratum
radiatum. Of the 93 cells analyzed, 83, or 89.2%, expressed detectable nAChR mRNA. Figure
2 quantifies the number of mRNA subunits found in each cell. We found that each cell had an
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average of 3.8 (± 0.22 S.E.M.) mRNA subunits detected with a slight kurtosis and skewness to
the left.
The simplified summary of expression is given in Table 3 which reports the proportion of
expression of the number of cells in which at least one subunit was expressed divided by the total
number of cells expressing at least one nAChR mRNA subunit (n=83). Somewhat surprisingly,
the α3 subunit was one of the most common subunits expressed, found in 54% of the
interneurons examined. In addition, the α4 subunit had the lowest expression of the subunits
analyzed (27%). Figure 3 shows the relative expression of each subunit as histograms
normalized to the median expression level for all nAChR subunits detected. This result
highlights the high level of expression and the larger number of cells that express the α3, β2, and
α5 mRNA subunits. The α4 histogram reiterates the small number of cells expressing α4, but
adds that the relative expression levels are low as well when compared to the average fold
expression (Figure 3).
To extend the proportion analysis further, we calculated the most commonly coexpressed pairs of subunits. The two subunits that co-express at the highest rate are the α3 and
β2 (n=69, cells expressing at least 2 subunits) (Table 4).
A Mann-Whitney test of all subunits examined showed that only the α3 had a
significantly different relative expression in the stratum oriens compared to the stratum
radiatum, with the stratum oriens having overall larger values of expression (p =0.0165, α3
stratum oriens, mean±SEM = 3.47±1.11, α3 stratum radiatum, mean±SEM = 1.24±0.21). The
α2 subunit and α4 subunit had p-values that were not quite significant, but a larger sample size
may reveal the true trend (α2 p=0.0603, stratum oriens larger; α4 p=0.0945, stratum radiatum
larger).
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In addition, we calculated the Pearson r values for subunit co-expression regardless of
location in the stratum oriens or stratum radiatum (Figure 4.A). Our results show that all of the
β mRNA subunits are highly correlated with each other. Also, the α5 and α3 fold expression
levels are moderately correlated with the β2 mRNA subunit (Figure 4.A). The α5 mRNA
subunit is also moderately correlated with the β4 subunit (Figure 4.A). Lastly, no other subunits
appear to be correlated regarding mRNA expression levels.
We then assessed all the Pearson r values dependent on area. The stratum radiatum
results show a wide range in correlation values (Figure 4.B). The range is similar to the stratum
oriens; however, the stratum oriens appears to have two groupings (those not correlated and
those with very strong correlations, Figure 4.B). Therefore, we tested the Pearson r correlation
values for significance across the stratum oriens and stratum radiatum. Table 5 summarizes our
results. We only tested values greater than 0.9 in either the stratum oriens or stratum radiatum.
Surprisingly, all our tests show significance p-values (p<0.05, two-tailed).
In addition to 2-way subunit combinations, we also analyzed all 3-way, 4-way, 5-way, 6way, 7-way, and 8-way combinations that were observed. The expected values were calculated
by simply multiplying the portion of expression for each subunit in the combination (values from
Table 3). As an example, the expected proportion co-expressing α2 + α3 would be 0.37 X 0.54 =
0.2, or 20%. The actual proportion of cells observed with both α2 + α3 was 0.23. Therefore, the
Observed/Expected value is 1.1, very close to what would be expected. A z-test of two
proportions indicated that 63 different combinations appeared more often than expected
(significant if p<0.01) (Table 6).
Table 7 lists all the mRNA subunit combinations we observed, as well as their location in
either the stratum oriens or stratum radiatum. The two most common combinations were
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α3α4α5α7β2and α3α5β2β3β4. The former occurred 4 times solely in the stratum radiatum
while the later appear 2 times in the stratum radiatum and 2 times in the stratum oriens.
Our analysis revealed 59 combinations of mRNA subunit expression in the 93 cells tested.
Of the 93 cells, 10 cells did not have detectable levels of expression and 42 cells had a unique
combination of mRNA subunits. Using the coverage estimation calculation provided by Chao
and Lee (1992), we estimated that we had 49.4% coverage.
Estimated sample coverage = 1 - (# single observations / # of total observations)
= 1 – (42/83)
= 0.494
This implies that our data collection only accounted for about one-half of all the possible mRNA
subunit combinations expressed in CA1 interneurons. Chao and Lee also provide a way to
calculate the estimated number of possible combinations.
= (# of combinations observed) / coverage
= 59 / 0.494
=119.4
Therefore, there are likely at least 119 different mRNA subunit combinations that could be found
in the CA1 of the rat hippocampus.
Discussion
Our results are not able to completely differentiate nAChR mRNA subunit expression
between the stratum oriens and the stratum radiatum. However, they do bring to light some
interesting conclusions. Namely, the high rate of expression of the α3 mRNA subunit and the
overall diversity with an estimated 119 different combinations of mRNA subunit expression.
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We would like to add to these results and explore changes in subunit concentrations
during development (Alkondon, 2007, Gahring, 2005, Rogers, 1998, Winzer-Serhan, 2005). The
role of nAChRs in development may be quite diverse considering that nAChRs are found on
glial cells, pyramidal cells, and neurons (Didier, 1995). Therefore, we feel it imperative that
future studies should focus on understanding early development of the hippocampus. This could
improve treatment of ADHD or early interventional therapies for ASD. Likewise, understanding
normal aging as opposed to dementia or AD may improve targeted therapies since some nAChR
subtypes have been shown to be sensitive to β-amyloid (Pettit, 2001, Wang, 2000).
Previous studies reporting quantitative mRNA expression between strata radiatum and
oriens found higher proportion of interneurons expressing α2 in the stratum oriens and a higher
proportion of interneurons expressing α5, β2, and β4 in the stratum radiatum (Sudweeks 2000,
Khiroug, 2004). This study, however, indicated no significant difference in the detection of these
subunits between the two strata (stratum radiatum: n=45 samples each ran in triplicate, stratum
oriens: n=38 samples each ran in triplicate). Yet, we did find a significant difference in α3
expression between the two strata. These discrepancies may have resulted in differences in the
number of PCR cycles performed. In the study mentioned above, sixty-five cycles were run on
their target transcripts, while we measured amplification across seventy-five cycles of PCR.
Running a higher number of amplification cycles may have afforded us a more sensitive analysis
of the target mRNAs. Additionally, with the high level of diversity demonstrated in the
hippocampal interneurons, it should not be surprising that different samples would highlight
different results.
Considering that only the α3 mRNA subunit had statistically different expression levels
in the stratum oriens and stratum radiatum we found the results in Figure 4 and Table 5 quite
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surprising. We expected the correlations between regions to not be statistically different
considering the expression levels were not different (except α3). This may suggest different
functional roles of the stratum oriens and stratum radiatum. Figure 4.B showing more polarized
groupings of the Pearson r values in the stratum oriens could suggest a more selective expression
of subtypes than the stratum radiatum which shows a broader range its Pearson r values. This
could indicate a difference in the functional properties of nAChRs in each strata.
One interesting result is that of those interneurons that expressed only 1 subunit the
majority of those interneurons expressed the α7 mRNA. Since the α7 subunit can form a
homomer those results are expected. However, there were a few interneurons with sole detection
of β2, β4, or the α5 mRNA subunit. However, none of the other subunits investigated here form
homomeric channels. The results are likely the result of the snapshot view of mRNA levels at
any one time in the interneuron. mRNA levels likely rise and fall in response to cellular
communication.
The high levels of co-expression of α3 and β2 were somewhat surprising because the α3
has only been shown to be in the medial habenula and the sympathetic ganglion (Yeh, 2001).
However, our results suggest that that the α3 subunit has a significant role in hippocampal
interneurons. Since the α3 and β2 subunits had the highest overall expression and the highest coexpression rate, it highlights the importance of further characterizing the α3β2 nAChR (Jackson,
2017).
We suggest that the α3β2, and even the α3β4 nAChRs, may play a more important role in
the hippocampus than the α4β2 nAChRs. Our results also suggest that α3 containing cells
frequently expressed α5 mRNA as well. This may suggest a likely incorporation of α5 subunits
into α3 containing nAChRs. Not as surprising were the relatively abundant α7 mRNA
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expression results. They appear to be fairly average in the relative expression levels and the
proportion of expression. This validates the use of α7 targeted therapies. Considering that α3 is
found in very few regions of the brain and α7 has a more ubiquitous expression, α3 targeted
therapies may prove effective (Vernallis, 1993, Ullian, 1997, Lindstrom, 1996, Yeh, 2001).
Future studies may include reconstituting the significant combinations of nAChR subunit
co-expression (Table 4) into cellular expression systems such as Xenopus laevis oocytes. Studies
using expression systems benefit from the finer controllability of diffusion rates and drug
application concentrations versus interneurons within the brain slice. Findings from
electrophysiological recordings in response to pharmacological application can then be used to
elucidate the characteristics and contributions of the significant nAChR subunit co-expression
combinations identified in this study (Table 4). These studies would then help us understand the
role of nAChRs in modulating hippocampal function. Further pursing these results may identify
networks or subpopulations in the hippocampus and throughout the CNS affected in the
pathogenesis of neurodegenerative diseases and ultimately give rise to the discovery of
treatments that prevent or abate these disorders. The results in this study are a gateway to the
characterization of the diverse range of hippocampal nicotinic receptor subtypes.
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Table 1.1: Summary of Amplicon Lengths (base pairs) and Oligo Sequences of the nAChR
Subunit Probes Used in qPCR.
Real-time PCR probes

Length

Probe

nAChR β2 rat

77 bp

CCCAGCCAAGCCCTGCACTGAT

nAChR β3 rat

145 bp

AAGGACCCCATGGACCGCTTCT

nAChR β4 rat

72 bp

CTGGTCAGGGTCCCTCATCCCAG

nAChR α2 rat

103 bp

CTCCATGGCTCCCCGGATCTGAA

nAChR α3 rat

68 bp

TTGAACCTGCTCCCCAGGGTCATG

nAChR α4 rat

356 bp

TGGGTGAAGCAGGAGTGGCACGA

nAChR α5 rat

77 bp

TGTCTTTGCCATCAACATCCACCACC

nAChR α7 rat

214 bp

CAAGAGCTCCTGCTACATTGACGTTCGC

18s rRNA rat

133 bp

TGGAGCGATTTGTCTGGTTAATTCCGATAAC
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Table 1.2: Summary of Oligo Sequences of the nAChR Subunit Primers (+ and -) Used in
qPCR.
Real-time PCR
primers

+ Primer

- Primer

nAChR β2 rat

CTGCGGCTGACCCATGTAC

TGGGCTCAGCTCGGAAAG

nAChR β3 rat

CCCGAGATGGCTTTGCAT

GGAAAGCGACCAGAACTCTTTC

nAChR β4 rat

CGTCCCGGTCTTGAAGTCA

CAGTATCAGCTGTGGCCAAGTG

nAChR α2 rat

TGCCCAGGTGGCTGATG

CATGTTAGTCTCTAGCCAATGG
TATGA

nAChR α3 rat

TTGGGTCAAGGCCGTGTT

TCACCACTGGTCGGCCTAGT

nAChR α4 rat

CCAGATGATGACAACCAACG

CCACACGGCTATGAATGCTC

nAChR α5 rat

GATTTTCGTGACCCTATCCAT
TATG
GCGTTGTGTGTGGAGGAAGA

nAChR α7 rat

TTGCCAGTATCTCCCTCCAG

CTTCTCATTCCTTTTGCCAG

18s rRNA rat

GTGCATGGCCGTTCTTAGTT
G

GCCACTTGTCCCTCTAAGAAGT
TG
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Table 1.3: The Proportion of Cells Containing Each nAChR mRNA Subunit (n=93). Ten of the
93 interneurons tested did not contain detectable levels of any nAChR mRNA subunit analyzed.
Proportion of Cells
containing each subunit
Subunit

Proportion

α3

0.54

β2

0.54

α5

0.43

α7

0.42

β4

0.42

β3

0.40

α2

0.37

α4

0.27
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Table 1.4: The Proportion of Subunit Co-expression for the Highest 8 Subunit Pairs (n=69, the
number of cells that contained at least 2 mRNA subunits).
Subunit Co-expression of nAChR mRNA
Percentage

Subunit Co-expression

52%

α3 and β2

49%

α3 and α5

44%

α7 and β2

42%

α5 and β2

41%

α3 and β4

41%

β2 and β4

39%

α3 and β3

38%

β2 and β3
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Table 1.5: T-test for Pearson Correlation Coefficients for Subunit Co-expression in the stratum
oriens and the stratum radiatum. The selected comparisons were done because at least one
location (oriens or radiatum) had a Pearson correlation coefficient >0.90. All regions analyzed
showed significance in at the 0.05 level using a two-tailed t-test.

Comparison of Pearson Correlation Coefficients
subunit subunit Stratum oriens

Stratum radiatum

p-value

α3

α5

0.961

0.361

<0.0001

α3

β4

0.987

0.937

0.00527

α5

β2

0.996

0.053

<0.0001

α5

β3

0.986

0.858

<0.0001

α5

β4

0.926

0.118

<0.0001

β2

β3

0.989

0.428

<0.0001

β2

β4

0.944

0.759

0.00829

β3

β4

0.938

0.565

0.00022
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Table 1.6: A Summary of all mRNA Subunit Combinations Observed More Often than
Would be Expected (observed/expected>1). Expected values were calculated by multiplying
the proportion values from Table 3.
Combination
α3+α5
α3+α4+α7
α3+α5+β2
α3+α5+β3
α3+α5+β4
α3+β2+β3
α3+β2+β4
α3+β3+β4
α4+α7+β2
β2+β3+β4
α2+α3+α5+β3
α2+α3+α7+β2
α2+α3+β2+β3
α2+α4+α7+β2
α2+α7+β2+β3
α3+α4+α5+α7
α3+α4+α5+β2
α3+α4+α7+β2
α3+α4+α7+β3
α3+α4+α7+β4
α3+α4+β2+β3
α3+α4+β2+β4
α3+α4+β3+β4
α3+α5+α7+β2
α3+α5+α7+β3
α3+α5+β2+β3
α3+α5+β2+β4
α3+α5+β3+β4
α3+α7+β2+β3
α3+α7+β2+β4
α3+α7+β3+β4
α3+β2+β3+β4

Observed/Expected
1.6
2.7
2.2
2.3
2.3
2.1
2.0
2.4
3.0
2.3
2.9
2.4
2.6
3.9
3.0
4.1
3.9
4.6
3.6
3.4
2.8
3.3
3.6
3.3
3.1
3.5
3.5
4.5
3.3
2.7
3.4
4.0

Combination
α4+α5+α7+β2
α4+α7+β2+β3
α4+α7+β2+β4
α4+α7+β3+β4
α4+β2+β3+β4
α5+α7+β2+β3
α5+α7+β2+β4
α5+α7+β3+β4
α5+β2+β3+β4
α7+β2+β3+β4
α2+α3+α7+β2+β3
α3+α4+α5+α7+β2
α3+α4+α7+β2+β3
α3+α4+α7+β2+β4
α3+α4+α7+β3+β4
α3+α4+β2+β3+β4
α3+α5+α7+β2+β3
α3+α5+α7+β2+β4
α3+α5+α7+β3+β4
α3+α5+β2+β3+β4
α3+α7+β2+β3+β4
α4+α7+β2+β3+β4
α5+α7+β2+β3+β4
α2+α3+α5+α7+β2+β3
α2+α3+α7+β2+β3+β4
α3+α4+α5+α7+β2+β3
α3+α4+α5+α7+β3+β4
α3+α4+α7+β2+β3+β4
α3+α5+α7+β2+β3+β4
α4+α5+α7+β2+β3+β4
α3+α4+α5+α7+β2+β3+β4
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Observed/Expected
4.1
4.5
3.4
4.0
3.1
3.3
2.6
3.2
3.9
3.4
4.9
7.7
6.6
6.3
7.4
5.8
5.7
4.4
6.0
7.3
6.4
7.4
6.0
8.5
8.7
11.6
12.4
13.8
11.1
12.4
23.0

Table 1.7: A List of All Observed Subunit mRNA Combinations by Location.

Combination
No nAChR
mRNA
α2
α3
α4
α5
α7
β2
β3
α2α3
α2α7
α2β2
α2β4
α3β4
α4α7
α5β4
α7β3
α7β4
α2α3α5
α2α3β2
α2α7β2
α2β3β4
α3α4α7
α3α5α7
α3α5β2
α3α5β3
α3α7β3
α7β2β4
α2α3α5β3
α2α3α5β4
α2α3β2β3

Number of
Occurrences
(Radiatum)
4
2
1
1
1
2
2
2
1
2
1
1
1
1
1
1
2
1
1
1
1
1

Number of
Occurrences
(Oriens)
Combination
6
1
1
1
1
1
1
1
1
1
1
1
1
1
2
-

α2α4α7β2
α2β2β3β4
α3α4β2β4
α3α5β2β4
α3α7β2β3
α3β2β3β4
α4α5β2β4
α4α7β2β3
α5α7β2β3
α5α7β2β4
α2α3α4α5β 2
α2α3α4α7β2
α2α3α5β3β4
α2α4α7β2β3
α3α4α5α7β2
α3α4α5β2β4
α3α4α5β3β4
α3α5β2β3β4
α2α3α4α7β2β4
α2α3α5α7β2β3
α2α3α5β2β3β4
α2α3α7β2β3β4
α3α4α7β2β3β4
α3α5α7β2β3β4
α2α3α4α5α7β2β3
α2α3α4α7β2β3β4
α2α3α5α7β2β3β4
α3α4α5α7β2β3β4
α2α3α4α5α7β2β3β4
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Number of
Number of
Occurrences Occurrences
(Radiatum) (Oriens)
1
1
1
1
1
1
1
1
4
1
2
1
1
2
1
1

1
2
1
1
1
1
1
2
1
1
1
1
2
3
1

Figure 1.1

Figure 1.1: Kinetically Diverse Population of nAChRs. This figure is a representation of the
diversity of responses while patching onto rat hippocampal interneurons. The arrow indicates a
1 second, 1 mM ACh application. Patches were made on the neuron cell bodies.
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Figure 1.2
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Figure 1.2: Count of nAChR Subunit Expression. A histogram reporting the number of nAChR
mRNA subunits detected using qPCR (n=83). The average number of subunits per cell was 3.8
± 0.22 (mean±SEM) with slight kurtosis and skewness to the left.
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Figure 1.3
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Figure 1.3: nAChR Subunit Relative Expression by Subunit. All nAChR mRNA subunits have
variable expression levels as indicated by the histograms. Relative expression levels were
binned with 1 being the mean fold expression of the cells.
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Figure 1.4

A.

B.

Figure 1.4: Pearson r Correlations of the Average Fold Expression for 2-way Comparisons.
A. Correlations of combined data from both the stratum oriens and stratum radiatum. B.
Correlations of both the stratum oriens and stratum radiatum. The stratum radiatum has a
greater variability in Pearson r values while the stratum oriens has Pearson r values centered near
zero and a separate group with values greater than 0.90. Noted correlations listed from smallest
to largest.
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Abstract
The hippocampal interneuron population is diverse yet almost always contains nicotinic
acetylcholine receptors (nAChRs). The nAChRs regulate the release of GABA on to
glutamatergic pyramidal cells. The highest co-expressed nAChR subunits in the Amun’s horn
(CA1) of the rat hippocampal interneurons are the α3 and β2 subunits yet the α3β2 subtype(s)
has not been extensively characterized.
We expressed the human α3β2 nAChRs in Xenopus laevis oocytes to differentiate
possible subtypes using two-electrode whole cell voltage clamp. We can distinguish at least two
subtypes based on their acetylcholine (ACh) and nicotine affinities. Regarding acetylcholine,
injecting 5X more β2 mRNA gives an EC50=12 μM±1.7, while injecting 5X more α3 mRNA
gives an EC50=264±1.6 μM. Additionally, these mRNA ratios yields significant differences in
rise time, half width, and ACh desensitization (p<0.05). The desensitization after 30 seconds of
ACh exposure revealed the clearest kinetic differences between subtypes.
In summary, the human α3β2 neuronal nAChR subunits can form at least two different
and functional subtypes that can easily be distinguished with long term ACh applications. These
hippocampal subtypes could provide new drug targets for cognitive therapies for diseases such as
Alzheimer’s Disease (AD), Autism Spectrum Disorder (ASD), and Attention Deficit
Hyperactivity Disorder (ADHD).
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Introduction
Neuronal nicotinic acetylcholine receptors (nAChRs) are important in the synchronous
firing of the hippocampus (Grybko, 2010, Ji, 2000). These receptors are found in the
interneurons of the hippocampus (Cobb, 2005, Winzer-Serhan, 2005, Jones, 1997).
Hippocampal interneurons are relatively sparse compared to pyramidal cells and glial cells, but
are necessary in cognition as evidenced by the cognitive drugs that target nAChRs (Dannenberg,
2015, Bezaire, 2016). Overall, the nAChR population in the interneurons is extremely
heterogeneous and not fully characterized (Sudweeks, 2000, Szabó, 2014, Jackson, 2017). Patch
clamp recordings of the rat hippocampus reveal a large diversity of electrophysiological
properties indicating a large diversity of receptors subtypes (Figure 1). Rates of subunit coexpression in the rat hippocampus indicate that the α3 and β2 subunits are the highest coexpressed subunits within the stratum oriens and stratum radiatum of the CA1 (Amun’s horn)
(Jackson, 2017). Yet, the α3β2 nAChR subtypes have not been differentiated.
Cognitive therapeutics targeting nAChRs in the hippocampus are only mildly effective
and often target the α7 containing nAChRs (Wallace, 2011, Aracava, 2005, Martin, 2004, Leiser,
2009, Soderman, 2011, Thomsen, 2010). Other nAChR-targeted therapies often target the α4β2
nAChR (Rode, 2012, Timmerman, 2012, Sater, 2009). Both the α7 homomer and α4β2
heteromer are found throughout the brain. However, the α4 subunit is expressed at relatively
low levels among the CA1 hippocampal interneurons and may be one reason why cognitive
therapies targeting the α4β2 are only mildly effective (Jackson, 2017). The α7 is often found
pre-synaptically and helps regulate neurotransmitter release (Liu, 2003). Due to the high coexpression level of α3β2 and possible different location within the neuron we feel that α3β2
subtypes should be fully investigated as possible drug targets. The α3β2 nAChR has been
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somewhat characterized (Chavez-Noriega, 1997, Wang, 1998, Chavez-Noriega, 2000, Wu, 2008,
Wang, 2015), but the distinction between two different α3β2 subtypes has not been explored.
Like the α4β2 and the α2β2 nAChRs, we believe that there are at least 2 stoichiometries of the
α3β2 nAChR (Papke, 1989, Ussing, 2013, Zwart, 1998, Khiroug, 2004, Dash, 2014). We are
excited about the possible therapeutic targets that α3β2 nAChRs could serve as for various
diseases affecting the hippocampus such as Alzheimer’s disease (AD), autism spectrum disorder
(ASD), ethanol and/or nicotine addiction, and attention deficit hyperactivity disorder (ADHD)
(Kamens, 2009). Therefore, we sought to characterize the kinetic properties of the α3β2
nAChRs, and differentiate possible subtypes.
Methods
Plasmids containing human α3 (hα3) and human β2 (hβ2) genes were transformed into
One Shot® E. coli chemically competent cells, and plasmid DNA was then isolated and purified
using the HiSpeed® plasmid purification kit. Plasmids containing the hα3 and hβ2 genes were
linearized by restriction digest with SacI. The mRNA was then transcribed, capped on the 5’ end,
a poly(A) tail was added (optional), and LiCL purification was performed using the mMessage
mMachine® T7 Ultra Kit according to the protocol provided. RNA was re-suspended in TrisEDTA Buffer, mixed in various ratios, aliquoted, and stored at -20˚C. For some nAChR subtypes,
the poly(A) tail appears to increase expression yield. However, we had similar results with or
without the poly(A) tail addition.
Ratios of hα3 (1.0 µg/µL) and β2 (1.0 µg/µL) AChR subunit mRNAs were injected into
Xenopus laevis oocytes. Naive Xenopus laevis oocytes are not responsive to ACh, but when
injected with the appropriate mRNA they are also able to express a high yield of nAChR protein.
The ratios of α3:β2 1:5 and α3:β2 5:1 were used to increase the likelihood of expression of each
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probable stoichiometry (α3(2)β2(3) and α3(3)β2(2) respectively) (Nelson, 2003, Moroni, 2006). Each
oocyte was injected with 50.6 nL of mRNA for a total of 50.6 ng of mRNA per oocyte. The
injection needles and recording needles were made of borosilicate glass. Following injection, the
oocytes were stored in Ringer’s solution (OR-2-Ca2-pen-strep) at 17-19˚C for 6-9 days on a rocker
(pH~7.5). This solution consists of (in mM unless noted): 82 NaCl, 2.5 KCl, 1 Na2HPO4, 5
HEPES, 1 CaCl2, 1 MgCl2, 0.5 theophylline, 100,000 units penicillin, and 10 mg streptomycin.
After 9 days any oocytes not recorded on were stored at 4˚C to stop further maturation of the cell
until the oocyte was used for recordings.
Recordings of the cell’s electrical activity were obtained through two-electrode voltage
clamp. Traces were recorded using Clampex 9.2 software and analyzed on ClampFit 9.2. Various
concentrations of Acetylcholine (ACh) and Nicotine (Nic) were suspended in OR-2 solution and
were perfused (1 psi) over the oocyte every 90 seconds and the cell’s responses were recorded
(ACh concentrations between 100 nM and 100 mM; Nic concentrations between 1 mM and 1.5
M). Except for the desensitization tests, ACh was perfused for 3 seconds every 90 seconds and
nicotine was perfused for 1 sec every 90 seconds. To measure the degree of desensitization, the
EC85 (effective concentration 85% of maximum response) for each subtype was applied for 60
seconds with a 2 minute wash between applications (replicates of 3). We did not blind our
experiments since the protocols for ACh and nicotine were different. In order to analyze the
response, it was necessary to know the ligand and the exact concentrations applied.
For voltage clamp recordings, the oocytes were clamped at -60 mV while solutions were
perfused at 17 ml∙min-1. The IV plot was generated by clamping the oocyte at -90, -75, -60, -45,
-30, -15, 0 (all in mV), and then we performed the same procedures as the voltage clamp
recordings. All ligands were dissolved in OR-2-Ca2+ without theophylline, streptomycin, and
44

penicillin. Solutions were perfused using an 8-valve (pinch), computer controlled, pressurized
perfusion system. Oocytes were impaled with microelectrodes filled with 3 M KCl and a resistance
between 0.1-2 MΩ. Clampex 9.2 was used to run the electrophysiology protocols through a
GeneClamp 500B amplifier and Digidata 1322A digitizer. Data was sampled at 5 kHz and filtered
at 2 kHz. Peak amplitudes ranged from 3 nA to 200 nA. The range in peaks was dependent on
each oocytes protein expression level as well as the concentration of acetylcholine used to generate
the response.
All recordings were normalized to the maximums (EMAX) for each subtype. This was
necessary since each oocyte expressed a different number of channels based on health, efficiency,
and incubation time. Upon collection of the recordings, we used Clampfit to analyze multiple
parameters for each recording including rise time, half-width (width of the peak at 50% of the peak
amplitude), and desensitization. For our analysis, we compared the 1:5 and 5:1 results at the EC50
(10 µM, 333 µM respectively) and the EC85 (333 µM, 10 mM respectively).

However, for

desensitization we only compared the EC85. Analysis of the steady state currents were compared
at 30 seconds during the 60 second ACh application.
Data and Statistical Analysis
Analysis of previously collected qPCR data (Jackson, 2017) was extended to determine if
there was more than one stoichiometry of the hα3 and the hβ2 nAChR. Microsoft Excel (2013)
was used to analyze the data for all figures except Figure 2 and Figure 4. Specifically, the
“=AVERAGE()” and “=STDEV()/(SQRT(COUNT()))” were used to calculate the mean and
standard error of the mean. These values were then used to generate Figure 1 using “Insert Bar
Graph” (Excel, 2013). Likewise, Figure 5A-B and Figure 6 were generated using the same
calculations and tools. Also, the approximate EC50 and approximate EC85 (effective
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concentration 85% of maximum response) were used as the points of comparison for the kinetic
parameters (rise time and half-width). The data points for Figure 3 were also generated using the
formula for mean and standard error of the mean. However, a scatterplot fitted with a linear
trendline is more appropriate to present this data than a bar graph. Only the first 5 points of
Figure 3 were fitted for the trendline because the data shows a strong inwardly rectifying
channel. Fitting the line linearly better estimates the reversal potential of an inwardly rectifying
channel. Figure 4 was generated using GraphPad Prism v. 4. The data was fit using the
“sigmoidal dose-response (variable slope)” tool. The hill slopes, EC50 values, and R2 values, as
well as their respective standard errors, were provided in the curve fit analysis. Grubb’s outlier
tests were used to for all data sets (alpha=0.05). For statistical tests, p<0.05 is used as the level
to determine significance (*). We report all means and standard errors of the mean as 𝑥𝑥̅ ±SEM.

GraphPad InStat v. 3 was used to calculate all ANOVAs. ANOVAs were calculated as

“ordinary” and assumed to be Gaussian distributions. Tukey post-hoc tests were performed only
if the p<0.05. Figure 2.A and 2.B are example traces that were collected using Clampex 9.2 and
analyzed with Clampfit 9.2 (Axon Instruments). Screen shots were taken and then cropped in
Paint (Windows 7). Figure 2.C and 2.D were generated using Adobe Illustrator CC (2017). Also,
since each oocyte varies in the number of nAChR proteins it expresses it is necessary to
normalize the data for comparison.
Materials
Plasmids: hα3 (Origene# SC126406), hβ2 (Origene# SC309051), pCMV6-XL4 plasmid: OriGene
Technologies Inc., 9620 Medical Center Drive, Suite 200, Rockville, MD, USA, 20850.
One Shot® E. coli chemically competent cells (Invitrogen), mMessage mMachine® T7 Ultra Kit:
Thermo-Fischer Scientific 168 Third Avenue, Waltham, MA, USA, 02451.
HiSpeed® plasmid purification kit: Qiagen, 19300 Germantown Road, Germantown, MD, USA,
20874.
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SacI restriction enzyme: New England Biolabs, 240 Country Road, Ipswich, MD, USA, 019382723.
Tris-EDTA Buffer: BioExpress Corporation, 420 N Kays Dr, Kaysville, UT, USA 84037.
Defolliculated Xenopus laevis oocytes. Animal husbandry and surgery using anesthesia
and analgesia were performed by Ecocyte BioScience. 111 Ramble Ln #109, Austin, TX,
USA, 78745.
Oocyte injection, Nanoject II microinjector: Drummond Scientific Company, 500 East Park Way,
Broomall, PA, USA 19008.
Injection (1.12 mm OD x 0.51 mm ID) and recording (1.5 mm OD x 1.17 mm ID) capillary tubes:
Harvard Apparatus, 84 October Hill Road, Holliston, MA, USA, 01746.
Needles were pulled using Model P-97 puller: Sutter Instrument Company, 1 Digital Drive,
Novato, CA, USA, 94949.
Data acquisition software for electrophysiological recordings (Clampex 9.2) and recording
analysis (Clampfit 9.2). GeneClamp 500B amplifier. Digidata 1322A digitizer. Axon
Instruments, Molecular Devices, 1311 Orleans Drive, Sunnyvale, CA, USA, 94089.
Reagents for OR-2 Ca2+ solution: NaCl, KCl, Na2HPO4, HEPES, CaCl2, MgCl2, theophylline,
penicillin, streptomycin; Acetylcholine chloride, Nicotine tartrate: Sigma-Aldrich, 3050
Spruce Street, St. Louis, MO, USA, 63103.
Pinch valve perfusion system (product #s 13-pp-54, and 09-08). Automate Scientific Inc., 3271
Adeline Street, Unit B, Berkeley, CA, USA, 94703.
GraphPad Prism v. 4 and GraphPad Instat v. 3.05: GraphPad Software Inc., 7825 Fay Ave #230,
La Jolla, CA 92037 USA.
Microsoft Excel: Microsoft Building 92, 15010 NE 36th St, WA 98052-6399 USA.
Results
The qPCR data previously collected indicated that the α3 and β2 nAChR subunits are the
highest co-expressed subunits in the rat CA1 hippocampal interneurons (specifically, the stratum
oriens and stratum radiatum) (Jackson, 2017). Further analysis revealed that the mRNA is
expressed in a 1:1 (α3:β2) ratio. However, no individual interneuron expressed a 1:1 ratio.
Instead, we found that about half had greater α3 expression, while the other half had greater β2
expression. The two populations showed either a 3:1 ratio or a 1:3 of α3:β2 mRNA on average
(Figure 1).
Injection of hα3 and hβ2 mRNA into Xenopus laevis oocytes at a 1:5 and 5:1 revealed
two functional receptor subtypes. Both subtypes responded to ACh application; however,
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extended ACh applications at their respective EC85 revealed distinct kinetic differences (Figure
2).
The IV plot shows a similar reversal potential between the subtypes suggesting that there
is no difference in ion selectivity. Also, the reversal potential suggests that, like other nAChR
subtypes, the channels are permeable to both Na+ and K+ (Figure 3). The IV plot also shows that
both subtypes are strong inwardly rectifying channels.
The dose-response curves (Figure 4) reveal a statistical difference in the ACh and
nicotine affinities when comparing subtypes (ANOVA p<0.0001, p<0.0001 respectively, Table
1). The 1:5 injected ratio has greater affinity for ACh and nicotine than the 5:1 injected group.
We also show that both subtypes have a lesser affinity for nicotine (Figure 4.B). The 1:5
injected ratio, like ACh, has a greater affinity for the ligand (Table 1). However, Figure 4.B
reveals a bi-phasic curve for the 5:1 injected oocytes. Since, the dose-response curves for
nicotine are more separated than the dose-response curves for ACh it is easier to fit the biphasic
model.
In addition, we used t-tests to compare the peak amplitude for each injection ratio. When
comparing the EC85 and the EC50 values on the ACh dose-response curve, the peak amplitudes
for the 5:1 are statistically different at each (p<0.0001, p<0.001) with the 5:1 injections resulting
in larger currents. Likewise, we compared the EMAX of nicotine (333 M for 1:5, 1 M for 5:1) and
found a significant difference in the relative peak sizes as well. Like ACh, the 5:1 injection ratio
resulted in larger peak amplitudes.
Our results of the kinetic properties show that when applying ACh for only 3 seconds, the
two subtypes are more similar than different. However, there are two parameters that are
statistically significant: the half-widths and rise-times (Figure 5). Yet, the results differ

48

depending on concentration. Figure 6 reveals the most distinguishable characteristic: with
extended 60 second ACh applications, the two subtypes show marked differences in
desensitization. The 1:5 injected oocytes are significantly more desensitized at their steady state
than the 5:1 injected oocytes. After 30 seconds only 12.6±1.4% remained for the 1:5 oocytes
while 81.6±2.1% (𝑥𝑥̅ ±SEM) of the original peak amplitude remained for the 5:1 oocytes (Figure
6).
Discussion
The data suggests that there are at least two likely stoichiometries for the α3β2 nAChR.
The nicotine dose-response curves appear to be a mixture of α3β2 subtypes. The 1:5 nicotine
dose-response curve does not show a biphasic curve because it only represents the lower nicotine
concentrations where certain subtypes may not be activated. The biphasic may not represent all
of the possible stoichiometries, but the two most likely based on α4β2 and α2β2 stoichiometries
(Covernton, 2000, Houlihan, 2001, Bussion, 2001, Exley, 2006). The ACh dose-response curve
for the 1:5 injected oocytes, like the nicotine curve, appears best fit with a monophasic sigmoidal
dose-response curve. However, even though the 5:1 injected oocytes also fit best with a
monophasic sigmoidal dose-response curve, there are a few points on the curve that would
suggest multiple contributing subtypes. However, the ACh dose-response curve are two close to
distinguish considering. The 5:1 injection would increase the likelihood of α3(3)β2(2) subtypes
expression over the α3(2)β2(3) subtype expression. In addition, our results indicate that the
α3(2)β2(3) is either less efficient in formation resulting in overall smaller peak amplitudes, or has
lower efficacy. To determine if efficiency or efficacy or both are contributing to peak amplitude
size, single channel recordings would be necessary.
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One explanation for the increase in peak amplitude with the 5:1 injected oocytes is that
there is another possible binding site at the α3/α3 junction. Like the α4β2 nAChR, when more
α4 is present it has been suggested than an additional binding site is found at the additional
α4/α4 junction (Moroni, 2006). This may also be true of the α3β2 nAChR. However, this is
simply one explanation. The α3(3)β2(2) may simply be a more favored protein expression. Since,
the nH are similar, the different stoichiometries may have the same likelihood for channels
opening. A larger nH could indicate greater cooperativity of the binding sites. Yet, by simply
having more binding sites, this may increase the likelihood of binding without a change in the
cooperativity of binding.
Regarding nicotine, our EC50 values are larger than those previously reported (Wang,
1998), but previous studies do not distinguish between α3β2 subtypes. However, Wang et al.
used nAChRs transfected in HEK cells whereas we used Xenopus laevis oocytes. We hope to
follow up our research using HEK cells as well to confirm our findings regarding both injection
ratios.
When considering how other nAChR subtypes assemble and the qPCR data from Jackson
(2017), the data suggests that there are two likely stoichiometries: the α3(2)β2(3) (from a 1:5
mRNA ratio) and the α3(3)β2(2) (from a 5:1 mRNA ratio) (Papke, 1989, Zwart, 1998, Nelson,
2003, Khiroug, 2004). The injection ratios will likely not produce a homogenous population of
one stoichiometry, but our results indicate that there are enough of each stoichiometry to
distinguish their kinetic properties even though the nicotinic curve is biphasic (Figure 4.B). It
has been shown previously that sometimes a low, or broad, nH (hill slope) may indicate multiple
contributing stoichiometries, but considering the error bars and the fit of our curves, we are
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likely getting very little contribution from the less likely stoichiometries of (α3)1(β2)4 and
(α3)4(β2)1.
The most noteworthy difference between the two injected subgroups is desensitization
with prolonged ACh application. The 1:5 injected oocytes are much more easily desensitized
than the 5:1 injected oocytes. However, contrary to the α4β2 nAChR published results, the
desensitization of ACh on the α4β2 nAChR also increases with more β2 subunit expression
(Zwart 1998, Nelson, 2003, Carbone, 2009). Like the α4β2 and α2β2 ACh dose response curve
increasing the number of β2 subunits in the subtype also increases the ACh affinity and shifts the
dose-response curve left (Papke, 1989, Zwart, 1998, Nelson, 2003, Khiroug, 2004).
The β2 nAChR subunit has been shown to be widely expressed throughout much of the
rat brain (Hill, 1993). However, expression of the α3 subunit is much more restricted, being
previously identified in the sympathetic ganglion, medial habenula, and the autonomic ganglion
(Vernallis, 1993, Ullian, 1997, Lindstrom, 1996, Yeh, 2001). They have also been identified
outside of the nervous system in the adrenal gland (Campos-Caro, 1997), thymus (Mihovilovic,
1993), respiratory epithelial cells (Zia, 1997), and keratinocytes (Grando, 1995, 1996). With the
identification of the α3 subunit being highly expressed in hippocampal interneurons (Jackson
2017), the characterization of the α3β2 nAChRs is beneficial. We can now add it to the list of
nAChR subtypes that should be screened for cognitive drug development.
Current nAChR therapies target either the α7 or the α4β2 subtypes (Sarter, 2009). Also
since the α3β2 appears to be more restricted to hippocampal interneurons, drugs targeting the
α3β2 may be more selective than current therapies. Likewise, drugs targeting the α3β2 subtype
may alter the hippocampal firing to a different degree, or in a different manner current therapies.
There is even the possibility of combining α3β2 targeted therapies with current therapies in cases
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where such would be beneficial. Many cognitive diseases like AD and ASD currently have few
effective treatment options. Therefore, characterization of a new protein target in the
hippocampus may widen the possible therapeutics and give further insight into disease
development.
In conclusion, multiple α3β2 nAChR subtypes have been identified. Although similar in
many respects they do have distinguishable properties. Both subtypes are valid novel targets for
cognitive therapies and further research may yield great implications.
Supporting Information
Controls were done to ensure that the hα3 nor the hβ2 mRNA are not able to form a
functional nAChR by themselves. Following the methods previously outlined, we injected solely
hα3 mRNA or hβ2 mRNA, waited 7 days and then performed electrophysiological recordings
with ACh. The recordings were under the same conditions and restraints as all other recordings.
We found no evidence that the hα3 or the hβ2 forms a functional homomeric receptor.
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Table 2.1: Summary of ACh and Nic Dose-Response Curves.
Table 2.1
EC-50 (µM)
Hill Slope
R2

1:5 ACh

5:1 ACh

12±1.7

264±1.6

0.48±0.13

0.55±0.15

0.74

0.77

ANOVA

p<0.0001
1:5 Nic

5:1 Nic

25±1.5

21±1.6

1.0±0.46

1.4±0.90

EC-502 (mM)

N/A

415±7E18

Hill Slope2

N/A

15±1680

R2

0.67

0.57

EC-50 (mM)
Hill Slope

ANOVA

p<0.0001

53

Figure 2.1
1.B

1.A
Fold Expression ratio
of cells with more β2
1.00

1

0.5

Fold Expression ratio
of cells with more α3
1

0.41

0.5

0.30

0
α3

1.00

0

β2

α3

β2

Figure 2.1: Ratio of α3 and β2 Expression in Hippocampal Interneurons. The most commonly
co-expressed subunits, the α3 and β2, were analyzed further to identify two populations. (A)
56% of the interneurons tested in Jackson (2017) expressed in a 1:3 α3:β2 ratio. (b) 44% of the
interneurons tested in Jackson (2017) expressed in a 3:1 α3:β2 ratio. Of the 93 cells analyzed,
34 co-expressed α3 and β2. Therefore, n=19 for 1.A and n=15 for 1.B (total n=34).
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Figure 2.2
B.

333 µM ACh

10 mM ACh

1 nA

2 nA

A.

Figure 2.2: Sample Traces and Likely Stoichiometries. Injection of hα3 and hβ2 mRNA into
Xenopus laevis oocytes at a (A) 1:5 and (B) 5:1 ratio formed functional and distinguishable
receptors. The respective oocytes were perfused with 333 µM and 10 mM ACh for 60 seconds
to characterize desensitization. The likely stoichiometries are shown respectively.
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Figure 2.3
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Figure 2.3: IV Plot. 1:5 injected oocytes fit a linear trendline of y = 0.0356x + 1.033 (R² =
0.9892) (n=5) and fit a linear trendline for the 5:1 injected oocytes y = 0.0537x + 1.7478 (R² =
0.9362) (n=8) when fitting points between -90 mV and -30 mV. The reversal potential for both
is approximately -30 mV.
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Figure 2.4
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Figure 2.4: Dose-Response Curves. A. ACh Dose-Response. 1:5) EC50=12.2±1.7 μM,
nH=0.49±0.13 (R2=0.74) (n=14 oocytes, replicates of 4, 1 individual data point identified as an
outlier and removed). 1:5) EC50=263.8±1.6 μM, nH=0.55±0.15 (R2=0.77) (n=12, replicates of 4,
2 individual data points outliers). The 1:5 injected ratio has a minimum response at ~100 nM
and an Emax at ~1000 µM ACh. The 5:1 injected ratio has a minimum response at ~10 µM and
an Emax at ~33 mM ACh (ANOVA, F[15, 258]=54.644). A. Nicotine Dose-Response. 1:5) EC50=
25.3 ±1.5 mM, nH= 1.04±0.46 (R2=0.6705) (n=6 oocytes, replicates of 3, but not at all
concentrations were used for each oocyte, 1 individual data point was identified as an outlier and
removed.) (ANOVA, p<0.0001, F[12, 238]=30.396 5:1) EC50_1=21.2±1.6 mM, nH_1= 1.41±0.91,
EC50_2= 414±7E18 mM, nH_2=14.85±1680 (R2=0.57) (n=11 oocytes, replicates of 3, but not at all
concentrations were used for each oocyte, 3 individual data points were identified as outliers and
removed.)
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Figure 2.5
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Figure 2.5: Comparison of Rise Time and Half-Width of ACh Dose-Response Curve.
Comparisons were made at the EC50 (10 µM, 333 µM) and the EC85 (333 µM, 10 mM) for the
1:5 and 5:1 mRNA injected ratios respectively. A. Comparison of 10% to 90% rise time. 1:5) 10
µM (𝑥𝑥̅ =mean±SEM) 𝑥𝑥̅ =1166±237 ms (n=6, replicates of 3), 333 µM 𝑥𝑥̅ =169±9 ms (n =21,
replicates of 4, 3 replicate outliers removed). 5:1) 333 µM 𝑥𝑥̅ =821±123 ms (n=13, replicates of 4),
10 mM 𝑥𝑥̅ =1424±171 ms (n=25, replicates of 4, 3 replicate outliers removed). B. Comparison of
half-width. 1:5) 10 µM 𝑥𝑥̅ =3084±130 ms (n=5, replicates of 3, 3 replicate outliers removed), 333
µM 𝑥𝑥̅ =3522±654 ms (n=11, replicates of 4). 5:1) 333 µM 𝑥𝑥̅ =3988±163 ms (n=13, replicates of 4,
2 replicate outliers removed), 10 mM 𝑥𝑥̅ =3003±297 ms (n=21, replicates of 4).
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Figure 2.6

Desensitization
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Figure 2.6: Desensitization. Comparisons were made after 30 seconds of continuous ACh
application at the EC85. The 1:5 injected oocytes (n=7, replicates of 3, 1 replicate outlier
removed) were much more desensitized with very little of the original peak remaining while the
5:1 injected oocytes (n=3, replicates of 3, 1 replicate outlier removed) was only desensitized
minimally with much of the original peak remaining at 30 s. A t-test was used to test for
significance.
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Abstract
The activity of 3-furan-2-yl-N-p-tolyl-acrylamide (PAM-2) was compared among human
(h) α7 and α7β2 nicotinic acetylcholine receptors (AChRs), heteromeric hα1β2γ2 and
homomeric hρ1 GABAA receptor subtypes (GABAARs), and homomeric hα1 glycine receptors
(GlyRs) by electrophysiological methods. The patch-clamp results indicated that although PAM2 did not affect GlyRs and slightly decreased the activity of hρ1 GABAARs (i.e., 300 μM PAM-2
decreased the activity by 30 ± 1%), it moderately enhanced the activity of hα1β2γ2 GABAARs
(EC50 = 56 ± 7 μM; Emax = 131 ± 4%) compared to control (100%). These results confirmed the
high selectivity of PAM-2 for α7 AChRs. The voltage-clamp results indicated that PAM-2
potentiates hα7 AChRs mainly by increasing current intensity (EC50 = 141 ± 1.74 μM; Emax =
230%) with higher efficacy than that observed in hα7β2 AChRs (EC50 = 186 ± 1.35 μM; Emax =
190%). The molecular docking and dynamics results show that PAM-2 interacts differently
between the hα7 and hα7β2 models. More specifically, PAM-2 interacts with the archetypic
intrasubunit site as well as with the ECD-TMD junction in the hα7 model, whereas it interacts
with different ECD-TMD sites in the h(α7)2(β2)3 and h(α7)3(β2)2 stoichiometries. The
combination of functional and structural results suggest that the potentiating effect elicited by
PAM-2 is determined by its interaction with the intrasubunit site, whereas its activity is mediated
by its interaction with junctional sites.
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Introduction
Positive allosteric modulators (PAMs) with high selectivity for α7 nicotinic acetylcholine
receptors (AChRs) have generated a lot of expectation since these compounds might be used for
the treatments of different neurological disorders producing fewer side effects than agonists
(reviewed in Arias, 2010; Chatzidaki and Millar, 2015). Among them, PAM-2 (3-furan-2-yl-N-ptolyl-acrylamide) enhances agonist-induced α7 AChR activity in a temperature-sensitive manner
and reactivates desensitized α7 AChRs supporting a type II PAM classification, with certain
resemblance to type I PAMs when studied at the single-channel level (Arias et al., 2011;
Targowska-Duda et al., 2014; Andersen et al., 2016). In conclusion, PAM-2 has pharmacological
properties that are in between of type I and type II PAMs, which makes it a distinct α7 PAM.
Previous functional studies demonstrated the PAM-2 has positive allosteric modulatory
activity on α7 AChRs, whereas it inhibits human (h)α3β4, hα4β2, hα4β4 AChRs, slightly inhibits
N-methyl-D-aspartate (NMDA)-sensitive glutamate receptors (GluRs), slightly potentiates αamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-sensitive GluRs, and affects
neither kainate-sensitive GluRs, serotonin type 3 receptors, Nav1.2 and Kv3.1 voltage-gated ion
channels, acetylcholinesterase, nor β-amyloid content, indicating that this ligand presents high
receptor selectivity (Arias et al., 2011; 2015a; 2016; Andersen et al., 2016). Nevertheless, the
activity of PAM-2 between homomeric α7 and heteromeric α7β2 AChRs has not been studied
yet. Interestingly, functional α7β2 AChRs have been characterized in different neuronal types,
including hippocampal GABAergic interneurons (Khiroug et al., 2002, Liu et al., 2012; Wu et
al., 2016), and forebrain cholinergic neurons (Liu et al., 2009). Since inhibition of hippocampal
α7β2 AChRs by β-amyloid might be significant for the observed memory and learning
disabilities found in Alzheimer’s disease patients (Liu et al., 2012), the modulatory activity
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elicited by PAM-2 might alleviate these cognitive problems. To start delineating this supposition,
we initiated this study by comparing the activity of PAM-2 between hα7 and hα7β2 AChRs
expressed on Xenopus laevis oocytes by whole-cell voltage-clamp recordings.
Glycine receptors (GlyRs) and γ-aminobutyric acid type A (GABAARs), two major
inhibitory receptor members from the Cys-loop ligand-gated ion channel superfamily where
AChRs also belong (reviewed in Arias, 2011), are important for learning and memory processes
(reviewed in Xu and Gong, 2010). GABAARs are potentiated by structurally different
compounds, including neurosteroids, benzodiazepines, and barbiturates, and the major adult
isoform, α1β2γ2 GABAAR, is expressed in brain areas related to cognitive function such as
cerebral cortex and hippocampus (reviewed in Sigel and Steinmann, 2012). In addition, GlyRs
are potential targets for analgesic and anti-inflammatory drugs, and α1 containing GlyRs are
selectively potentiated by ginkgolic acids which are the active components for the antidepressant
activity found in Ginkgo biloba lipophilic extracts (Maleeva et al., 2015, and references therein).
This evidence supports the notion that these receptor subtypes could be modulated by other
PAMs. To determine whether the observed procognitive (Potasiewicz et al., 2015; 2017),
promnesic (Targowska-Duda et al., 2016), antidepressant-like (Targowska-Duda et al., 2014;
Arias et al., 2015), anti-nociceptive and anti-inflammatory (Bagdas et al., 2015) effects elicited
by PAM-2 are related to these receptor subtypes, the activity of this ligand was determined on
heteromeric hα1β2γ2 and homomeric hρ1 GABAAR subtypes as well as on homomeric hα1
GlyRs by whole-cell patch-clamp techniques.
Considering that the PAM-2 structure has an amide link susceptible to the metabolic activity
of amidases from the liver and/or brain (Pop, 1997), the activity of the potential metabolites ptoluidine and 3-(2-furyl)acrylic acid were also tested on the hα7 AChR. Since N,N′69

dicyclohexylurea was found as a byproduct in the synthesis of PAM-2, the PAM activity of this
compound was also tested on the hα7 AChR.
Previous molecular docking and molecular dynamics experiments using the Torpedo AChR
as the template for the construction of the hα7 AChR, demonstrated that the potential active sites
for PAM-2 are localized in the transmembrane domain (TMD) (Arias et al., 2016). More
specifically, PAM-2 interacted with the intrasubunit site already characterized for PNU-120596,
the archetype of type II PAMs, and also with an intersubunit site located between two α7-TMDs
that had not been previously characterized and might be important to define the pharmacological
differences observed between PNU-120596 and PAM-2 and other type I PAMs (Andersen et al.,
2016). By comparing the structural components of the docking sites between the homomeric hα7
and heteromeric hα7β2 AChRs, we demonstrated that PAM-2 binds to the archetypical
intrasubunit site in the hα7 AChR as well as to an intersubunit site in the h(α7)2(β2)3 model.
Interestingly, this structural difference correlates with the functional results indicating that PAM2 potentiates hα7 AChRs mainly by increasing current intensity with higher efficacy than that at
hα7β2 AChRs.
Materials and Methods
Materials
Glycine (Gly), γ-aminobutyric acid (GABA), penicillin (5000 U/mL)-streptomycin (5
mg/mL), acetylcholine chloride (ACh), fetal bovine serum (FBS), poly-L-lysine hydrobromide,
and Dulbecco's Modified Eagle Medium (DMEM) were purchased from Sigma-Aldrich (St.
Louis, MO, USA). PAM-2 was synthesized as described previously (Arias et al., 2011). Xenopus
laevis oocytes were purchased from Ecocyte Bioscience (Austin, TX, USA). Plasmids containing
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the hα7 and hβ2 subunit genes were purchased from Origene Technologies (Rockville, MD,
USA). One Shot® E. coli chemically competent cells were obtained from Invitrogen (Carlsbad,
CA, USA). HiSpeed® plasmid purification kit was obtained from QIAGEN Inc. (Valencia, CA,
USA). TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0) was purchased from Bioexpress (Layton,
UT, USA). PolyJet™ DNA In Vitro transfection reagent was obtained from SignaGen
Laboratories (Rockville, MD, USA). Trans-IT 293 transfection reagent was purchased from
Mirus, Bio LLC (Madison, WI, USA). Salts, solvents, and reagents were purchased from
commercial suppliers and used as received.
Voltage-Clamp Recording on Xenopus laevis Oocytes Expressing hα7 or hα7β2 AChRs
The hα7 (Origene# SC124074-20) and hβ2 (Origene# SC309051) mRNAs were prepared
using the respective subunit gene in the pCMV6-XL4 plasmid. The plasmids were transformed
into One Shot® E. coli chemically competent cells, and then isolated and purified using the
HiSpeed® plasmid purification kit. Plasmids containing the hα7 and hβ2 genes were linearized
with XBa1 and AvrII, respectively (New England BioLabs Inc., Ipswich, MA, USA). The
mRNA was then transcribed, capped on the 5’ end, and a PolyA tail was added using the
mMessage mMachine® T7 Ultra Kit (Ambion, Carlsbad, CA, USA). mRNAs were isolated by
LiCl purification, resuspended in Tris-EDTA Buffer, aliquoted, and stored at -20 °C until used.
Human α7 (0.2 or 1.0 µg/µL) and β2 (1.0 µg/µL) AChR subunit mRNAs were injected
into X. laevis oocytes using a Nanoject II microinjector (Drummond Scientific Company,
Broomall, PA, USA). The injection and recording needles of borosilicate glass were pulled by
using Model P-97 puller (Sutter Instrument Company,Novato, CA, USA). For homomeric hα7
AChRs, oocytes were injected with 50.6 nL of 0.2 µg/µL hα7 mRNAs. For heteromeric hα7β2
AChRs, the hα7 and hβ2 mRNAs were injected at either the [1:1] or [1:5] hα7:hβ2 ratio (1.0
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µg/µL:1.0 µg/µL, 0.2 µg/µL:1.0 µg/µL). The rationale being that a [1:5] (i.e., 0.2:1 µg/µL) ratio
would be more likely to produce a higher yield of heteromeric hα7β2 AChRs and relatively less
homomeric hα7 AChRs. However, the resulting recordings using either ratio were not
statistically different from each other (One-way ANOVA of rise times, decay times, and peak
currents, p>0.05), indicating the presence of hα7β2 AChRs in oocytes injected with either
hα7:hβ2 ratio.
Following injection, the oocytes were incubated for 7-9 days on a rocker between 17-19
°C and stored in OR-2-Ca2+ (Ringer’s solution, extracellular solution) (pH 7.5) with penicillinstreptomycin (10,000 units/mL; 10 mg/mL).
For the two-electrode whole-cell voltage clamp recordings, ligands were perfused on
oocytes clamped at -60 mV. All ligands were dissolved in OR-2-Ca2+, whereas PAM-2 was
dissolved in 1% DMSO. Control experiments showed no significant difference in responses with
solutions containing 1% DMSO. Solutions were perfused using an 8-valve, computer controlled,
pressurized perfusion system (Automate Scientific, Berkeley, CA, USA). Each oocyte was
impaled with microelectrodes filled with 3 M KCl and a resistance between 0.1-2 MΩ.
Clampex 9.2 was used to run the electrophysiology protocols through a GeneClamp 500B
amplifier and Digidata 1322A digitizer. Data was acquired at 5 kHz and filtered at 2 kHz. The
data was analyzed using Clampfit 9.2 (Molecular Devices, Sunnyvale, CA, USA).
Patch-Clamp Recording of HEK293 Cells Expressing GABAARs or GlyRs
The HEK293 cell line stably expressing recombinant hα1β2γ2 GABAAR subunits or
transiently transfected with hα1 GlyR or hρ1 GABAAR subunits were used to investigate the effect
of PAM-2 on these receptors. The PolyJet™ DNA In Vitro and Trans-IT 293 transfection reagents
were used for transient transfection of the respective hα1 and hρ1 subunits. Briefly, 0.5 µg of hα1
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subunit cDNA was added to cells growing exponentially on poly-L-lysine coated coverslips
placed in a 35-mm culture dish. In the case of hρ1, 2 µg of hρ1 subunit cDNA and 2 µg of
enhanced green fluorescent protein cDNA was added to cells growing on glass coverslips. Cells
that showed expression of the green fluorescent protein were subjected to patch-clamp
electrophysiology, as described previously (Snell and Gonzales, 2015). Transfected cells were
used for electrophysiological analysis 24-48 h after the transfection.
Whole-cell patch clamp recordings were performed at room temperature (RT) (22-25 °C)
at a holding potential of -60 (hα1β2γ2 and hα1) or -70 mV (hρ1). Patch pipettes of borosilicate
glass (M1B150F, World Precision Instruments, Inc., Sarasota, FL, USA) were pulled using a P87 Flaming/Brown or a Sutter P-97 horizontal puller (Sutter Instrument Co., Novato, CA) to a tip
resistance of 6-9 MΩ. The pipette solution for the hα1β2γ2 GABAARs and hα1 GlyRs contained
(in mM): 140 CsCl, 10 EGTA, 10 HEPES, 4 Mg-ATP; pH 7.2. A coverslip containing
transfected cells was placed in a small chamber (∼1.5 mL) on the stage of an inverted light
microscope (Olympus IMT-2) and superfused continuously (5-8 mL/min) with the following
external solution containing (in mM): 125 NaCl, 5.5 KCl, 0.8 MgCl2, 3.0 CaCl2, 10 HEPES, 10
glucose, pH 7.3. The external solution for the hρ1 GABAAR contained (in mM): 137 NaCl, 5.4
KCl, 1.8 CaCl2, 1 MgCl2, and 5 HEPES; pH 7.4, whereas the internal recording solution
contained: 120 CsCl, 20 tetraehtylammonium chloride, 1 CaCl2, 2 MgCl2, 11 EGTA, and 10
HEPES; pH 7.2 (Snell and Gonzales, 2015). In this case, a Perfusion Fast-Step 77B (Warner
Instrument LLC., Hamden, CT, USA) equipped with an array of square capillary tubes was used.
GABA or Gly was prepared in extracellular solution and applied (10-s) to cells
containing the hα1β2γ2 GABAARs or hα1 GlyRs via gravity flow using a Y-shaped tube
positioned near the target cell. With this system, the 10-90% rise time of the junction potential at
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the open tip was 60-120 ms (Huang and Dillon, 1999). In the case of the hρ1 GABAAR, the
GABA control and PAM-2 containing test solutions were applied for 5 s. A washout period of 90
s followed each recording to ensure a return to baseline current readings was achieved before
proceeding to the next recording. Receptor currents were obtained using a patch clamp amplifier
(Axopatch 200A, Axon Instruments, Foster City, CA, USA) equipped with a CV201A
headstage, whereas a pClamp10.0 (Molecular Devices, Sunnyvale, CA, USA) on an inverted
fluorescence microscope equipped with a FITC fluorescence cube was also used to record hρ1
GABAAR currents.
The hα1β2γ2 GABAAR and hα1 GlyR currents were low-pass filtered at 5 kHz,
monitored on an oscilloscope and a chart recorder (Gould TA240), and stored on a computer
(pClamp 6.05, Axon Instruments) for subsequent analysis. Receptors were typically activated
with agonist concentrations corresponding roughly to the EC30 (10 µM; hα1β2γ2) (Huang et al.,
2001) or EC50 (9.4 µM; hρ1) value for GABA and the EC30 value for Gly (15 µM; hα1) (Chen et
al., 2004), respectively. These concentrations were chosen because produce minimal receptor
desensitization, which may confound interpretation of results. To monitor the possibility that
access resistance changed over time or during different experimental conditions, the current
response to a -5 mV voltage pulse was measured at the initiation of each recording and stored on
our digital oscilloscope. This stored trace was continually referenced throughout the recording. If
a change in access resistance was observed throughout the recording period, the patch was
aborted and the data were not included in the analysis.
The concentration-response relationship for PAM-2 on hα1β2γ2 GABAARs was analyzed
using the following logistic equation (Potasiewicz et al., 2015): IPAM-2/I = 1/[1 + (apparent
EC50/[PAM-2])nH], where I is the current amplitude determined in the absence of PAM-2 (control
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assigned as 100%), IPAM-2 is the potentiation induced by different concentrations of PAM-2 [PAM2], apparent EC50 is the PAM-2 concentration to produce half-maximal potentiation, and nH is the
Hill coefficient.
Statistical Analysis
The obtained data, expressed as the mean ± SEM, were analyzed using the Origin 6.0
Microcal Software. Statistical analyses were performed using one-way analysis of variance
(ANOVA) and t-test (paired or unpaired). Differences will be accepted as significant with p ≤
0.05.
Homology Modeling, Molecular Docking, and Molecular Dynamics
The amino acid sequences and numbering of the hα7, hα4, and hβ2 subunits were obtained
from the UniProt implemented in ExPASy Molecular Biology Server (http://www.us.expasy.org)
(Gasteiger et al., 2003). The hα7 sequence was aligned with the hα4 and hβ2 sequences using
Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/). Structural models of the hα7 as well
as of the h(α7)2(β2)3 and h(α7)3(β2)2 stoichiometries were built applying homology modeling
methods using the crystal structure of the hα4β2 nAChR obtained at 3.94 Å atomic resolution
[PDB ID: 5KXI; www.rcsb.org/pdb/home/home.do (Morales-Perez et al., 2016)] as template.
Modeller 9.14 was used to obtain 100 homology models for each template, and subsequently,
their Discrete Optimized Protein Energy profiles (Eswar et al., 2006) were assessed. The best
model of each template was assessed by its quality by Ramachandran plots, generated by using
the Schrödinger suite software (Schrödinger Release 2015-3: Maestro, version 10.3). The β2
subunit in both h(α7)2(β2)3 and h(α7)3(β2)2 stoichiometries was taken from the hα4β2 nAChR
crystal structure, and each model optimized using Desmond (Schrödinger suite software).
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For the molecular docking procedure, PAM-2 was first built using the semiempirical AM1
method included in Spartan 10 V.1.1.0 (Wavefunction, Inc. Irvine, CA, USA) as previously
described (Arias et al., 2016). AutoDock Vina (Trot and Olson, 2010) was used for docking
simulations of the flexible ligand into the extracellular (ECD) or transmembrane (TMD)
(including ECD-TMD junction) of the whole, rigid, nAChR model under study. The
energetically lower poses were selected from each cluster of superposed poses as described
previously (Arias et al., 2013; 2016).
To investigate the stability of the best scored complexes, 15-ns molecular dynamics (MD)
simulations were subsequently performed for PAM-2 docked to each binding site in the
respective AChR model, using Desmond v.3.0.3.1 (Bowers et al., 2006) and OPLS-2005 force
field. Each receptor-PAM-2 complex was inserted into 1-palmitoyl-2-oleoyl phosphatidylcholine
membranes, solvated with water, and the protein charges neutralized with 0.15 M NaCl as
described elsewhere (Arias et al., 2015; 2016). Each complex was first minimized and then
subjected to 1-ns MD in NVT (constant number of particles, volume, and temperature) ensemble,
followed by 15-ns MD in NPT (constant number of particles, pressure, and temperature)
ensemble with fixing constrains on protein backbone as previously described (Arias et al., 2015;
2016). Finally, each complex was simulated in NPT ensemble for 15-ns without any fixing
constraints. The total potential energy of each docked model was calculated using the OPLS2005 force ﬁeld according to Bowers et al. (2006).
Results
Different PAM-2 Activity Between hα7 and hα7β2 AChRs
Injection of hα7 mRNAs with or without hβ2 mRNAs into Xenopus laevis oocytes
resulted in functional hα7 and hα7β2 AChRs. For heteromeric hα7β2 AChRs, the hα7 and hβ2
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mRNAs were injected at either the [1:1] or [1:5] hα7:hβ2 ratio. The rationale being that a [1:5]
(i.e., 0.2:1 µg/µL) ratio would be more likely to produce a higher yield of heteromeric hα7β2
AChRs and relatively fewer homomeric hα7 AChRs. However, the resulting recordings using
different ratios were not statistically different from each other (One-way ANOVA of rise times,
decay times, and peak currents to PAM-2, p>0.05), indicating the presence of hα7β2 AChRs in
oocytes injected with either hα7:hβ2 ratio.
Regarding the first series of experiments, the electrophysiological recordings illustrate
that the pre-application of PAM-2 caused kinetic changes on both ACh-activated hα7 (Figure
1.A) and hα7β2 (Figure 1.B) AChRs. PAM-2 increased the peak amplitude on both receptor
subtypes. To differentiate the effect of PAM-2 between the hα7 and hα7β2 AChRs, two
protocols were developed. The concentration-response curves for PAM-2 (Figure 1.C) in the
presence of a fixed concentration of ACh was determined on each AChR subtype. Additionally,
the concentration-response curves for ACh were determined in the absence and presence of a
fixed concentration of PAM-2 (Figures 3.A-B). PAM-2 increased the peak amplitude of both
hα7 and hα7β2 (Table 1). At the maximal PAM-2 effect, there is not a significant difference in
the fold increase of the peak amplitudes between hα7 and hα7β2. However, because of the
differences in their PAM-2 EC50 values we observe that there is a statistical difference in relative
peak amplitude at 10 µM PAM-2 (p<0.01, t-test).
The concentration-response curves for PAM-2, with a fixed ACh concentration, showed
significant increases at all PAM-2 concentrations in rise time, half-width, and decay tau when
compared to controls that were not exposed to PAM-2 (Figs 2.A-C). These effects were similar
at all PAM-2 concentrations (i.e. ANOVA testing showed no significant difference between
PAM-2 concentrations). Therefore, we pooled the data from multiple PAM-2 concentrations for
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the following t-tests (significance level of 0.05, two-tailed). The rise time values for PAM-2 hα7
and PAM-2 hα7β2, although both significantly different from their respective baselines, were not
significantly different from each other (t-test against baselines p<0.01, p<0.01, respectively,
Figure 2.B). Likewise, half-width values from PAM-2 hα7 and PAM-2 hα7β2 were significantly
different from their respective baselines (hα7 p<0. 0001, hα7β2 p<0.00000001), but not from
each other.
The decay phase of the ACh induced currents was fit using a single exponential equation,
yielding tau values. Unlike the rise time and half-widths, the PAM-2 effect on the tau values is
statistically different for hα7 than for hα7β2 (p=0.00816, Figure 2.C). The hα7 does not show a
significant increase in the tau decay, but the trend shows a possible increase. Whereas, the
hα7β2 subtypes show a significant increase in the tau decay following PAM-2 exposure when
compared to their respective baselines (p=0.104, p<0.001). Additionally, the hα7β2 has a
significantly longer tau value following PAM-2 application compared to the hα7. This allows
the two subtypes to be distinguished using PAM-2.
The ACh concentration-response curves for hα7 and hα7β2 are not statistically different
from each other. Additionally, in the presence of PAM-2, the concentration-response curves
remain similar to each other (Figures 3.A-B; Table 2). PAM-2 significantly increased the rise
time values at the lower ACh concentrations for both hα7 and hα7β2 (Figures 3.C-D).
Additionally, 20 µM PAM-2 significantly increased the total area at ACh concentrations between
100 µM and 10 mM for both subtypes. In fact, at the maximum ACh concentration (10 mM)
PAM-2 (20 µM) differentiates between hα7 and hα7β2 AChRs because of the larger increase in
total area of the hα7 subtype (ANOVA, p<0.001, Figure 3.F). The hα7 26− fold as compared to
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the hα7β2 which AChRs by 26- and 6-fold, respectively (Figure 3.F, Table 1). This is a 4.5-fold
difference between the total current in the hα7 and hα7β2 treated with 20 µM PAM-2.
Although there is an increase in rise time for both subtypes when compared to the
controls, there is only a slight difference in the effect of PAM-2 either subtype (Figures 3.C-E).
The trend shows that hα7β2 AChRs may have longer rise times after PAM-2 applications. This
could indicate changes in the channel opening, ACh affinity, or desensitization properties. See
Table 2 for the summary of the fits and kinetic changes of Figures 3A-F.
Figure 4 shows the time dependence of the PAM-2’s effect on the peak amplitude and
current area for both hα7 and hα7β2 AChRs. Both parameters were significantly different than
that for the control after only 10 seconds of 20 µM PAM-2 application on both subtypes.
Interestingly, the effects became more pronounced over time with continued application of
PAM-2. We also observed that the PAM-2 effect was reversible over time. To more easily
differentiate the AChR subtypes and to ensure that the maximum effect on peak amplitude was
reached, the application of PAM-2 was continued for 4.5 min. The maximal effect of PAM-2 on
peak amplitude was reached at 1.5 min, whereas its effect on the current area continued to
increase during the entire application. Therefore, we selected 3 min as our point of comparison
for the experiments used in Figures 1-3.
Effect of PAM-2 on GABAAR and GlyR Function
To examine whether PAM-2 affects hα1β2γ2 and hρ1 GABAARs or hα1 GlyR activity,
different PAM-2 concentrations (i.e., 10-300 µM) were co-applied with 10 µM (Figure 4.A) or
9.4 µM GABA (Figure 4.B) or 15 µM Gly (Figure 5). The results indicated that PAM-2
potentiated GABA-activated hα1β2γ2 GABAAR currents (Figure 4.A) as well as inhibited hρ1
GABAAR activity (Figure 4.B) in a concentration-dependent manner. The maximum effects were
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observed with 300 µM PAM-2, where hα1β2γ2 currents were increased to 131 ± 4% (p<0.05),
whereas the hρ1 currents were decreased to 70 ± 1% (p<0.001) compared to control (100%)
(Table 1). The potentiating EC50 value for PAM-2 on hα1β2γ2 GABAARs was 56 ± 7 µM (Table
1). The calculated nH value (1.50 ± 0.20; Table 1) suggests a cooperative mechanism, which is in
agreement with the fundamental mechanism of PAMs. In the hα1β2γ2 subtype, the onset of the
PAM-2 effect was rapid and completely reversible within 2-3 min. On the other hand, PAM-2
had no effect on GlyR response (p>0.05) (Figure 5; Table 1).
Homology Modeling, Molecular Docking, and Molecular Dynamics of PAM-2 at the hα7,
h(α7)2(β2)3, and h(α7)3(β2)2 Models
PAM-2 was docked into the ECD or TMD (including ECD-TMD junction) of the whole
receptor model. Since PAM-2 activity does not involve the orthosteric sites (Arias et al., 2011),
this interaction was not included in Figure 6. Although the ECD is not involved in the PAM-2
activity (Andersen et al., 2016), the observed allosteric site in the h(α7)2(β2)3 model is shown in
Figure 6A. The MD results indicated that the interactions summarized in Table 3 are stable
during the 50-ns simulations. This is based on the consideration that a ligand in its respective
pocket is stable when the RMSD variance value is ≤0.5 Å (Arias et al., 2016). The RMSD mean
values for the 50-ns simulation and the RMSD variance values calculated during the last 10-ns
are included in Table 4.
In the hα7 model, PAM-2 interacted with both the archetypical intrasubunit and ECD-TMD
junction 1 sites (Figure 6). The results using this new hα7 model showed that PAM-2 interacts
with the intrasubunit site as previously described in the hα7 model built using the Torpedo
AChR as template (Arias et al., 2016). More specifically, PAM-2 interacted with residues from
M1 (i.e., Leu216, Cys219, Val220, and Ser223, and M4 (i.e., Thr461, Ile464, and Leu465). In
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junction 1, PAM-2 interacted with residues from the Cys-loop (i.e., Trp134, Phe135, Pro136, and
Phe137), pre-M1 segment (i.e., Thr208, Tyr210, and Gly212), M1 (Leu216), M2-M3 loop (i.e.,
Leu270 and Ile271), and M4 (i.e., Leu465, Ala468, and Pro469) (Figure 6A).
In the h(α7)2(β2)3 model, PAM-2 interacted with the ECD-TMD junction at three sites
called junction 2, and 3 (orientation 1 and 2), which are different from that characterized on the
hα7 nAChR (Figure 6A; Table 3). In junction 2, PAM-2 intercalated between both α7 and β2
subunits, interacting with the β1-β2 loop (i.e., α7-Lys46, β2-Glu47, and β2-Arg48), pre-M1 (i.e.,
β2-Phe211, β2-Tyr212, β2-Asn215, and β2-Leu216), and M2 (i.e., α7-Leu255, α7-Ala258, α7Glu259, α7-Ala263, β2-Leu257, β2-Lys260, and β2-Ile261) (Figures 6.A-B; Table 3). An Hbond is formed between the PAM-2 nitrogen of the amide moiety and the carbonyl oxygene from
the α7-Ala258 backbone. In junction 3 orientation 1, located within the β2 subunit, PAM-2
interacted with residues from the M2-M3 loop (i.e., Lys274 and Tyr275), M3 (i.e., Phe278, β2Thr279, and Leu282), and M4 (i.e., Cys361, Phe363, Gly364, Gly367, and Met368) (Figures
6.A-C). An H-bond is formed between the carbonyl oxygen of PAM-2 and the α7-Lys274
nitrogen moiety. In junction 3 orientation 2, PAM-2 also interacted with β2 residues from the
Cys-loop (i.e., His136, Phe137, Pro138, and Phe139, M1 (i.e., Ile217, Cys220, and Val221), M2M3 loop (i.e., Leu271, Val272, Tyr275, and Leu276), and M4 (i.e., Met368, Phe369, and
Pro372) (Figures 6.A-D; Table 3). Although two residues (i.e., β2-Tyr275 and β2-Met368) are
common for two orientations of PAM-2 at ECD-TMD junctioon 3 site at h(α7)2(β2)3 model,
there are three possible β2 subunits so these two bindings sites might not be overlapped.
In the h(α7)3(β2)2 model, PAM-2 interacted with ECD-TMD junction 1, 2, and 4, and
luminal sites. The junction 1 and 2 sites are observed in the hα7 and h(α7)2(β2)3 model,
respectively. In junction 4, PAM-2 docked between two α7 subunits, interacting with residues
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from the β1-β2 loop (i.e., Lys46 and Gln48) (this site has the same residue, α7-Lys46, as
observed in junction 2 from the h(α7)2(β2)3 model, so change the number but junction 2 is
between a7 and b2, while this junction 4 is between two a7 subunits. These are homologous sites
that need to be clearly stated, if you use different numbers, you are saying that are two totally
different sites), Cys-loop (i.e., Tyr129), and M2 (i.e., Glu259, Pro262, Ala263, and Thr264) from
one α7 subunit, and with residues from the ECD (i.e., Asp42, Val43), β1-β2 loop (i.e.,
Asp44 and Glu45), Cys-loop (i.e., Asn171, Gly172, Glu173, and Trp174), pre-M1 (i.e., Tyr211)
from an adjacent α7 subunit. Finally, PAM-2 interacted with the ion channel lumen, more
specifically with residues from positions 6’, 2’, and -2’, as well as with additional residues from
positions 5’, 1’, -3’, and -4’. Since the binding to this luminal site presented higher energy
compared to other non-luminal sites, and considering that PAM-2 does not block hα7 nAChRs at
potentiating concentrations (Arias et al., 2011; 2016), this interaction was not further considered.
Discussion
In electrophysiological recordings, the hα7 and hα7β2 are almost indistinguishable.
However, with enough replicates we can resolve that the rise time for the hα7 is slightly faster
than the hα7β2. This is likely because there are 5 possible ACh binding sites on the hα7
(Corringer, 2000, Changeux, 1998). In addition, the hα7 AChR only requires that one binding
site needs to be occupied for full receptor activation and subsequent channel opening (Andersen
et al., 2013). Therefore, the likelihood of channel opening is higher for the hα7. However,
saturating concentrations of agonists may induce rapid desensitization (Papke et al., 2000).
Whereas, the hα7β2 likely only has 2 or 3 ACh binding sites, depending on the subunit
stoichiometry, (likely hα72β23 or hα73β22) and multiple molecules of ACh are required for
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receptor activation. Since a α7:β2 1:5 ratio was injected, both hα72β23 and hα73β22 might be
expressed, producing events that are the result of both receptor stoichiometries. In sum, it is
likely that ACh more easily activates and desensitizes the hα7 than the hα7β2; yet, the
differences are so minute that it can be difficult to distinguish in vivo. Additionally, there are no
current pharmacological ways to distinguish the two subtypes in vivo during an
electrophysiological recording. Therefore, we thought it imperative to see if PAM-2 has a
distinguishable effect on the hα7 and hα7β2.
We found that the area under the curve, or total current, distinguishes the hα7 and hα7β2
in the presence of PAM-2. Since, there is a dramatic increase in area this may be evidenced of a
change in desensitization. This change in total area may be more evident in the hα7 because it is
natively in a more desensitized state. As a metaphor, the hα7 has a greater working distance, and
that the change in desensitization is more pronounced since it starts at a higher desensitized state.
The change in desensitization for each subtype is supported by the increase in rise time and the
increase in peak amplitude for each.
PAM-2 may slow the process of receptors moving from their open to their desensitized
states. The voltage clamp results also indicated that the activity of PAM-2 differs between hα7
and hα7β2 AChRs. Namely, PAM-2 increased the tau for the single exponential fit of decay
more for the hα7β2 than for the hα7. Both subtypes show an increase in the tau as compared to
the baselines, but the changes in the hα7β2 were more significant. Considering, there is not a
significant difference in the PAM-2 effect on hα7 and hα7β2 half-width and rise times, but only
on the decay phase, it may highlight distinct binding properties of PAM-2 on either subtype.
Interestingly we observed a shift in the ACh EC50 value to the right in the hα7β2 ACh
concentration-response curve in the presence of PAM-2. A shift to the left is expected for
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PAMs, however, in the presence of a PAM the higher the agonist concentration, the higher the
ion channel blockade. For this reason, we used 50 µM ACh (represents ~25% of the total peak
current for the hα7β2 and the hα7) for our PAM-2 concentration-response curve (Figure 1.C) In
the ACh concentration-response curve, even though the ACh EC50 in the presence of PAM-2 was
shifted to the left, the fold response is still greater compared to the control (Figure 3.B).
Regarding the PAM-2 concentration-response curve (Figure 1.C) we see sharp increases
in the nH, as well as maximum fold increases of 2.5 for the hα7 and 2.1 for the hα7β2. For both
subtypes, there is a concentration at which you reach the maximum fold increase and increasing
the PAM-2 concentration does not result in a more enhanced response. At 10 µM PAM-2, we
see a distinguishing difference between the effect of PAM-2 on the hα7 and hα7β2. In sum,
even though there are many indistinguishable properties between the hα7 and hα7β2, PAM-2
serves to distinguish the hα7 and hα7β2 from one another.
The patch clamp results indicated that PAM-2 induces only a modest potentiation of
GABA-activated hα1β2γ2 GABAAR currents and slight inhibition of hρ1 GABAAR currents, but
does not influence homomeric hα1 GlyR activity. Since the observed effects on GABAARs are
produced at non-clinically relevant concentrations, it is unlikely that GABAARs and GlyRs,
members of the same Cys-loop receptor superfamily as for α7 AChRs, might mediate the
beneficial effects elicited by PAM-2, including procognitive (Potasiewicz et al., 2015; 2016),
promnesic (Targowska-Duda et al., 2016), antidepressant-like (Targowska-Duda et al., 2014;
Arias et al., 2015), anti-nociceptive and anti-inflammatory (Bagdas et al., 2015) activities.
Considering that the PAM-2 structure has an amide link susceptible to the metabolic activity
of amidases from the liver and/or brain (Pop, 1997), the activity of the potential metabolites ptoluidine and 3-(2-furyl)acrylic acid were tested on the hα7 AChR. The functional results
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indicated that neither p-toluidine nor 3-(2-furyl)acrylic acid have activity (Table 1), discarding
the possibility of PAM-2 active metabolites produced by amidases from the liver and/or brain.
However, we cannot rule out the existence of other metabolic pathways producing additional
metabolites (e.g., methoxy metabolites) with potential activity. Since N,N′-dicyclohexylurea was
found as a byproduct in the synthesis of PAM-2, the PAM activity of this compound was also
tested on the hα7 AChR. The results showed no activity for N,N′-dicyclohexylurea, indicating
that this precursor is not responsible for the observed PAM-2 activity.
This new study using the crystal structure of the hα4β2 nAChR as the homology template
confirms previous results obtained with the hα7 model built using the Torpedo AChR as the
homology template (Arias et al., 2016). More precisely, these news results indicate that PAM-2
binds to the intrasubunit site characterized for PNU-120596, the archetypical type II PAM
(Young et al., 2008; daCosta et al., 2011; Arias et al., 2016). Recent findings using the
α7TSLMF mutant (i.e., Ser223Thr, Ala226Ser, Met254Leu, Ile281Met, and Val288Phe) also
showed that PAM-2 and PNU-120596 failed to potentiate the quintuple mutant, supporting the
notion that these two PAMs share the similar structural determinants within the intrasubunit site
(Andersen et al., 2016). This new study also confirms previous results (Arias et al., 2016),
indicating that PAM-2 interacts with the ECD-TMD junction at sites that are also observed at
both hα7 and h(α7)3(β2)2 nAChRs (i.e., junction 1), and at both h(α7)2(β2)3 and h(α7)3(β2)2
stoichiometries (i.e., junction 2-5), respectively. Interestingly, junction 1 is formed by residues
from α7 subunit, junction 3 from the β2 subunit, while junction 2 and 4 is formed by residues
located at the interface between α7 and β2 subunits or between two adjacent α7 subunits,
respectively.
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The existence of the ECD-TMD junction sites, located apart from the archetypical
intrasubunit site, might be important to understand the mechanisms underlying the dissimilar
activity of PAM-2 between the α7 and α7β2 nAChRs (this work) as well as the different features
found between type I and type II PAMs (Andersen et al., 2016; Arias et al., 2016).
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Table 3.1: Pharmacologic Activity of PAM-2 on hα7 and hα7β2 AChRs, hα1β2γ2 and hρ1
GABAARs, and hα1 GlyRs.
Receptor
Type

Method

hα7 AChR

Two-electrode voltage-clamp on
Xenopus oocytes injected with
hα7 subunit mRNA

hα7β2 AChR

Two-electrode voltage-clamp on
Xenopus oocytes injected with
hα7 and hβ2 subunit mRNAs
(1:5 ratio)

b

Pharmacologic
activity

Emax
(% control)

EC50
(μM)

nH

Potentiation

246 ± 25

8.8 ± 1.15

12.23 ±
13.26

(>100 µM)
PAM-2
(1-80 µM)

Inhibition
Potentiation

N/A
207 ± 26

N/A
19.5 ± 1.14

N/A
11.74 ±
28.14

(>100 µM)

Inhibition

N/A

N/A

hα1β2γ2
GABAAR

Whole-cell patch clamp on
HEK293 cells permanently
expressing hα1β2γ2 GABAARs

PAM-2
(10-300 µM)

Slight
Potentiation

131 ± 4

56 ± 7

N/A
1.50±0.2
0

hρ1
GABAAR

Whole-cell patch-clamp on
HEK293 cells transiently
expressing hρ1 GABAARs

PAM-2
(10-300 µM)

Slight
Inhibition

70 ± 1 a

~540 b

─

hα1 GlyR

Whole-cell patch clamp on
HEK293 cells transiently
expressing hα1GlyRs

PAM-2
(30-300 µM)

No effect

─

─

─

hα7 AChR

Two-electrode voltage-clamp on
Xenopus oocytes injected with
hα7 subunit mRNA

No effect

─

─

─

hα7 AChR

Two-electrode voltage-clamp on
Xenopus oocytes injected with
hα7 subunit mRNA
Two-electrode voltage-clamp on
Xenopus oocytes injected with
hα7 subunit mRNA

N,N′dicyclohexylur
ea
(30-300 µM)
p-Toluidine
(10 µM)

No effect

─

─

─

3-(2Furyl)acrylic
acid
(10 µM)

No effect

─

─

─

hα7 AChR

a

Ligand
(concentration
range)
PAM-2
(1-80 µM)

This value corresponds to PAM-2-induced inhibition relative to control (100%).
This IC50 value is just an estimation using three different concentrations.
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Table 3.2: Kinetics Parameters for ACh in the Absence (Control) and Presence of PAM-2 at the
hα7 and hα7β2 AChRs.
Kinetics
parameter
Peak
amplitude

hα7
Control

+ PAM-2

Control

+ PAM-2

ACh EC50 (µM)

194±1.17

141±1.74

144±1.12

186±1.35

nH

2.33±0.58

1.06±0.51

2.37±0.50

0.99±0.25

Maximal increase
(x-fold)
R2
ANOVA
Rise time

Maximal increase
(x-fold)
R2
ANOVA

Current
area

hα7β2

Maximal increase
(x-fold)
R2
ANOVA

2.3

▬

▬

1.9

0.734

0.424

0.646

0.552

▬

p<0.0001

▬

p<0.0001

▬

2.1

▬

3.6

0.760

0.132

0.445

0.520

▬

p<0.0001

▬

p<0.0001

▬

26.3

▬

5.9

0.537

0.258

0.684

0.439

▬

p<0.0001

▬

p<0.0001

The kinetics parameters are obtained from Figures 2A-F, respectively.
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Table 3.3: Molecular Interactions of PAM-2 with Allosteric Sites at the hα7 and hα7β2 Models.
nAChR
subtype

Binding site
location

Residues involved in ligand binding
ECD

Cys loop
W134
F135
P136
F137

ECD-TMD
junction 1
hα7

PreM1

M1

T208
Y211
G212

ECD
h(α7)2(β
2)3

ECD-TMD
junction 2

β2-I217
β2-C220
β2V221

89

L465
A468
P469

F275

β2K274
β2Y275

β2-H136
β2-F137
β2-P138
β2-F139

M4

T461
I464
L465

α7-L255
α7-A258
α7-E259
α7-A263
β2-L257
β2-K260
β2-I261

ECD-TMD
junction 3
Orientation
1
ECD-TMD
junction 3
Orientation
2

M3

L270
I271

L216

β2F211
β2Y212
β2N215
β2L216

α7-K46
β2-E47
β2-R48

M2M3
loop

L216
C219
V220
S223

Intrasubunit
α7-P17
α7-L18
α7-G83
α7-K87
α7-D89
α7-W86
α7H105
α7Y151
β2-P83
β2-H86
β2-F106
β2N109
β1-β2
loop:

M2
(position)

β2L271
β2V272

β2F278
β2T279
β2L282

β2-C361
β2-F363
β2G364
β2G367
β2M368
β2M368
β2-F369
β2-P372

Table 3.3: Continued: Molecular Interactions of PAM-2 with Allosteric Sites at the hα7 and hα7β2
Models.

α7-W134
α7-F135
α7-P136
α7-F137

ECD-TMD
junction 1

h(α7)3(β
2)2

ECD-TMD
junction 2

ECD-TMD
junction 4

α7Y210
α7Y211
α7N214

β1-β2
loop:
α7-E45
α7-K46
β2-R48
α7-D42
α7-V43
α7-D44
α7-E45
α7-K46
α7-Q48

α7T208
α7G212

α7-Y129
α7-N171
α7-G172
α7-E173
α7-W174

α7Y211

α7L216
α7V220

α7L215

β2-L256
β2-V257
α7-E259
β2-S259
α7-I260
β2-K260
β2-P264
α7-E259 (1’)
α7-P262 (1’)
α7-A263 (1’)
α7-T264 (1’)
α7-G237 (-3’)
β2-C237 (-4’)
α7-E238 (-2’)
β2-G238 (-3')
β2-E239 (-2’)
β2-M241 (1’)
α7-S241 (2’)
β2-T242 (2’)
α7-T245 (6’)
β2-I245 (5’)

Luminal
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β2Y275
β2L276
α7L270
α7I271
α7Y274
α7F275

α7T349
α7-I352
α7L353

Table 3.4: RMSD Mean and RMSD Variance Values for PAM-2 Interacting with Different
Nicotinic Receptor Subtypes, Including hα7, h(α7)2(β2)3, and h(α7)3(β2)2 nAChRs.

Binding site

nAChR subtype

hα7

h(α7)2(β2)3

h(α7)3(β2)2

ECD

-

2.051 ± 0.014
(0.002)

-

ECD-TMD
junction 1

0.6825 ± 0.008
(0.087)

-

1.599 ± 0.006
(0.017)

ECD-TMD
junction 2

-

0.9509 ± 0.010
(0.026)

0.9043 ± 0.008
(0.059)

1.892 ± 0.009
(0.059)

-

ECD-TMD
junction 3
Orientation 1

1.441 ± 0.008
(0.074)

ECD-TMD
junction 3
Orientation 2

-

1.014 ± 0.012
(0.004)

-

ECD-TMD
junction 4

-

-

1.785 ± 0.007
(0.002)

Luminal

-

-

1.446 ± 0.014
(0.007)

The RMSD mean values correspond to the 50-ns simulation, and the RMSD variance values were
calculated during the last 10-ns.

91

Figure 3.1
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Figure 3.1: Effect of PAM-2 on (A) Homomeric hα7 and (B) Heteromeric hα7β2 AChRs.
Acetylcholine (50 µM) was applied for 3 seconds activating each AChR subtype. Although PAM2 (50 µM) did not appear to affect AChR activity independently, a 3 minute pre-treatment of PAM2 altered the kinetic properties of both AChRs. We observed an increase in the peak amplitude and
total area. The hα7 and hα7β2 were both altered but, the kinetic changes of the hα7 were more
pronounced. (C) Effect of PAM-2 on the ACh-induced peak amplitude at the hα7 (■) and hα7β2
(□) AChRs. Increasing concentrations of PAM-2 (1-100 µM) were applied to either the hα7 (n=11)
AChR, while ACh was held constant at 50 µM. A 90 second PAM-2 wash was done between each
ACh application. The potentiating EC50, Emax, and nH values for PAM-2 at each AChR subtype
are summarized in Table 1.
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Figure 3.2
(B)

(A)

(C)

Figure 3.2: Change in Properties of Desensitization After a 3 minute PAM-2 Application.
(A) Pooled data of the half-width measurement (width of the peak in ms at 50% of the amplitude)
after PAM-2 application when compared to the baseline measurements before the PAM-2
application are statistically different for each subtype (α7 Pre-PAM-2 v. α7 PAM-2, pvalue<0.0001, α7β2 Pre-PAM-2 v. α7β2 PAM-2, p-value<0.00000001, t-tests). However, the
PAM-2 effect on the half-width for α7 and α7β2 are not statistically different, as well as their
comparison on their pre-PAM-2 baselines. (B) Pooled data of the rise-time (time required to
increase from 10% to 90% of the peak amplitude) after PAM-2 application when compared to the
baseline measurements before the PAM-2 application are statistically different for each subtype
(α7 Pre-PAM-2 v. α7 PAM-2, p-value=0.0042, α7β2 Pre-PAM-2 v. α7β2 PAM-2, p-value<0.0014,
t-tests). However, the PAM-2 effect on the rise-times for α7 and α7β2 are not statistically different,
as well as their comparison on their pre-PAM-2 baselines. (C) Pooled data of the tau for single
exponential fit of decay after PAM-2 application when compared to the baseline measurements
before the PAM-2 application are statistically different for on the α7β2 AChR (α7 Pre-PAM-2 v.
α7 PAM-2, p-value=0.104) (α7β2 Pre-PAM-2 v. α7β2 PAM-2, p-value<0.001, t-tests). In
addition, the PAM-2 effect on the tau for single exponential fit of decay for α7 and α7β2 were
statistically different (p-value=0.00816), even though the comparisons of their pre-PAM-2
baselines were not. ANOVAs revealed no significant differences in the desensitization properties
with various concentrations of PAM-2 (1 µM-100 µM), therefore, all data was pooled.
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Figure 3.3: Effect of 20 µM PAM-2 on Various Kinetic Parameters Obtained from ACh-induced
hα7 and hα7β2 AChR Responses.
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Figure 3.3 Continued: The activity of ACh on the respective hα7 (■) (n = 7) and hα7β2 ( ) (n =
14) AChR was compared to that obtained in the presence of 20 µM PAM-2 applied for 3 minutes
[hα7 (□), n = 4; hα7β2 ( ), n = 9]. The comparison of the relative peak amplitude for the (A)
hα7 (■) and (B) hα7β2 ( ) AChRs in the absence versus the presence of PAM-2 [(□), F[13,
118]=11.126, p<0.0001; ( ), F[12, 234]=35.956, p<0.0001] indicated a statistically significant effect
by PAM-2. The comparison of the time required for a pulse to rise from 10% to 90% of the peak
amplitude (i.e., relative rise time) for the (C) hα7 (■) and (D) hα7β2 ( ) AChRs in the absence
versus the presence of PAM-2 [(□), F[12, 111]=4.697, p=0.0011; ( ), F[9, 227]=44.602, p<0.0001]
indicated a statistically significant effect by PAM-2. The error bars are the S.E.M. values. The
apparent absence of error bars on certain points is due to the scale required for comparison.
(*p<0.05, **p<0.01, ***p<0.001). The quantitative parameters for ACh in the absence and
presence of PAM-2 at each AChR subtype are summarized in Table 2. (E) Comparison of the
difference between the largest PAM-2 effects and the largest control values on both hα7 (black
bars) and hα7β2 (white bars) AChRs. Although the peak amplitude and current area are
compared at 10 mM ACh, the rise time comparison is made at the minimum ACh concentration
because the effect inversely related. (F) The results summarize that PAM-2 has a much greater
potentiating effect on homomeric hα7 AChRs compared to that for heteromeric hα7β2 AChRs.
The quantitative parameters for ACh in the absence and presence of PAM-2 at each AChR
subtype are summarized in Table 2. (F) Fold increase in total current (area) increases with
increasing ACh concentrations during 20 µM PAM-2 applications for the hα7 AChRs.
However, even though the hα7β2 AChRs show a ~5 fold increase in total area during 20 µM
PAM-2 applications, the increase is not observed with increasing ACh concentrations.
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Figure 3.4
50 µM PAM-2 Application
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Figure 3.4: Time Dependence of the Change in Peak Amplitude and Current Area of the
Respective hα7 (■,□) and hα7β2 ( , ) AChR Perfused with 50 µM PAM-2.
A significant effect on peak amplitude (▬) and area (….) was observed after 10 seconds of
perfusion on both hα7 (peak, p<0.0001; area, p<0.0001; n = 6) and hα7β2 (peak, p<0.05; area,
p<0.001; n = 3) AChRs. T-tests were performed at 10 seconds in comparison to the control.
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Figure 3.5

Figure 3.5: Effect of PAM-2 on Heteromeric hα1β2γ2 (A) and Homomeric hρ1 (B) GABAARs.
(A) Top, representative traces showing GABA-activated hα1β2γ2 GABAAR currents, in the
absence and presence of PAM-2, by using whole-cell patch-clamp. Different concentrations of
PAM-2 (i.e., 10-300 µM) were co-applied with 10 µM GABA for 10 s. Bottom, the results
indicated that PAM-2 potentiated hα1β2γ2 currents in a concentration-dependent manner (n = 38). The potentiating EC50, nH, and Emax values were summarized in Table 1. (B) Top, representative
traces showing GABA-activated hρ1 GABAAR currents, in the absence and presence of PAM-2,
by using whole-cell patch-clamp. Different concentrations of PAM-2 (i.e., 10, 100 or 300 µM)
were co-applied with 9.4 µM GABA for 5 s. Bottom, the results indicated that PAM-2 slightly
inhibited hρ1 currents in a concentration-dependent manner (n = 3-8; paired t-test; p<0.01 and
p<0.001 for 100 and 300 µM, respectively). All current amplitudes are normalized to the response
in the absence of PAM-2 (assigned as 100%). Each data point represents Mean ± SEM. The
estimated IC50 and Emax (%) values are summarized in Table 1.
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Figure 3.6

Figure 3.6: Effect of PAM-2 on Recombinant hα1 GlyRs. Top, representative traces showing
Gly-activated hGlyR currents, in the absence and presence of PAM-2, by using whole-cell patchclamp. Different concentrations of PAM-2 (i.e., 30, 100 or 300 µM) were co-applied with 15 µM
Gly for 10 s. Bottom, the results indicated that PAM-2 did not affect GlyR function (n = 6-7;
paired t-test; p>0.05). All current amplitudes were normalized to the response in the absence of
PAM-2 (assigned as 100%). Each data point represents Mean ± SEM.
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Figure 3.7 (A)

(B)

(C)

(D)

Figure 3.7: Molecular Docking of PAM-2 to the hα7
and h(α7)2(β2)3 Models. (A) PAM-2 binding sites at
the hα7 [i.e., the intrasubunit (light blue) and ECDTMD junction 1 (purple) sites] and h(α7)2(β2)3 models
[i.e., the ECD allosteric (orange), ECD-TMD junction 2
(magenta), ECD-TMD junction 3 (yellow), and ECDTMD junction 4 (green) sites]. For clarity, one α7
subunit is hidden from the h(α7)2(b2)3 model, thus, the
order of explicitly shown subunits is (from left): β2
(gray), α7 (blue), β2 (gray), and β2 (gray). (B)
Molecular interactions of PAM-2 with the ECD-TMD
junction 2 site (magenta) at the h(α7)2(β2)3. This site, located in the α7/β2 interface, is formed
by residues from the β1-β2 loop (i.e., α7-Lys46, β2-Glu47, and β2-Arg48), pre-M1 (i.e., β2Phe211, β2-Tyr212, β2-Asn215, and β2-Leu216), and M2 (i.e., α7-Leu255, α7-Ala258, α7Glu259, α7-Ala263, β2-Leu257, β2-Lys260, and β2-Ile261). The black arrow shows the H-bond
formed between the PAM-2 nitrogen and the carbonyl oxygene from the α7-Ala258 backbone.
(C) Molecular interactions of PAM-2 with the ECD-TMD junction 3 site at orientation 1(yellow)
at the h(α7)2(β2)3. This site, located within the β2 subunit, is formed by residues from the M2M3 loop (i.e., Lys274 and Tyr275), M3 (i.e., Phe278, Thr279, and Leu282), and M4 (i.e.,
Cys361, Phe363, Gly364, Gly367, and Met368). An H-bond is formed between the carbonyl
oxygen of PAM-2 and the α7-Lys274 nitrogen moiety. (D) Molecular interactions of PAM-2
with the ECD-TMD junction 3 site at orientation 2 (green) at the h(α7)2(β2)3. This site is formed
only by β2 residues from the Cys-loop (i.e., His136, Phe137, and Pro138, and Phe139), M1 (i.e.,
Ile217, Cys220, and Val221), M2-M3 loop (i.e., Leu271, Val272, Tyr275, and Leu276), and M4
(i.e., Met368, Phe369, and Pro372). PAM-2 is rendered in ball (A) or stick (B-D) mode, whereas
residues as stick mode (element color code). All non-polar hydrogen atoms are hidden.
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REMARKS
Neuronal nicotinic acetylcholine receptors are highly targeted protein targets used in
treating many neurological conditions including cognition, depression, schizophrenia and
neurodegeneration (Freedman, 2014, Hurst, 2013). This research is the first of its kind
identifying and characterizing the subtypes of the α3β2 nAChR. We have hypothesized that
considering the high levels of mRNA α3 and β2 subunit coexpression that the α3β2 nAChR may
play a more significant role in hippocampus circuitry than previously believed. In addition,
considering the ratio of the mRNA subgroups we sought to differentiate α3β2 nAChR subtypes
using electrophysiology. Our results suggest there are at least two distinguishable subtypes of the
α3β2 nAChR. This novel result provides new drug targets for neurological conditions.
In addition, we found it intriguing and valuable to characterize PAM-2, an α7* selective
positive allosteric modulator, that may be promising drug in cognitive therapeutics (Uteshev,
2014). Positive allosteric modulators that target GABA receptors have been effective in the
treating anxiety, depression, and other mood disorders (Nickols, 2014). The current research also
suggests in addition to positive allosteric modulators being more effective in treating cognitive
disorders, they may also lend fewer negative side effects. Our research using PAM-2 sought to
different the PAM-2 effect on α7 nAChR homomers and α7β2 nAChR heteromers. We found
that although PAM-2 does have significant effects on both subtypes the effect is distinguishable.
Therefore, PAM-2 serves as one of the only methods of distinguishing α7 from α7β2 nAChR in
vivo.
The results of each chapter are significant to the field of pharmacology and neuroscience.
The enhanced understanding of nAChR subtypes and their positive allosteric modulators are a
gateway to many additional studies.
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